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8.1. General
Proctocolectomywith ileal pouch-anal anastomosis (IPAA) is the
procedure of choice for most patients with ulcerative colitis
(UC) requiring colectomy.1 Pouchitis is a non-specific inflam-
mation of the ileal reservoir and themost common complication
of IPAA in patients with UC.2–7 Its frequency is related to the
duration of follow up, occurring in up to 50% of patients 10 years
after IPAA in large series from major referral centres.1–9 The
cumulative incidence of pouchitis in patients with an IPAA for
familial adenomatous polyposis is much lower, ranging from 0 to
10%.10–12 Reasons for the higher frequency of pouchitis in UC
remain unknown. Whether pouchitis more commonly develops
within the first years after IPAA or whether the risk continues to
increase with longer follow up remains undefined.
Statement 8A
The diagnosis of pouchitis requires the presence of
symptoms, together with characteristic endoscopic
and histological abnormalities [EL3a, RG B]. Exten-
sive UC, extraintestinal manifestations (i.e. PSC),
being a non-smoker, p-ANCA positive serology and
NSAID use are possible risk factors for pouchitis
[EL3b, RG D]8.1.1. Symptoms
After proctocolectomy with IPAA, median stool frequency is 4
to 8 bowel movements,1–4,13,14 with about 700 mL of
semiformed/liquid stool per day,2,13,14 compared to a volume
of 200 mL/day in healthy people. Symptoms related to
pouchitis include increased stool frequency and liquidity,
abdominal cramping, urgency, tenesmus and pelvic discom-
fort.2,15 Rectal bleeding, fever, or extraintestinal manifesta-
tions may occur. Rectal bleeding is more often related to
inflammation of the rectal cuff (“cuffitis,” Section 1.4),16 than
to pouchitis. Faecal incontinence may occur in the absence of
pouchitis after IPAA, but is more common in patients with
pouchitis. Symptoms of pouch dysfunction in patients with IPAA
may be caused by conditions other than pouchitis, including
Crohn's disease of the pouch,17–19 cuffitis16 and an irritable
pouch20 among other conditions. This is why the diagnosis
depends on endoscopic and histological findings in conjunction
with symptoms.
8.1.2. Endoscopy (“pouchoscopy”)
Pouchoscopy and pouch mucosal biopsy should be
performed in patients with symptoms compatible with
pouchitis, in order to confirm the diagnosis.15,21 Patients
with an ileoanal pouch occasionally have a stricture at thepouch-anal anastomosis, so a gastroscope rather than a
colonoscope is preferred for pouchoscopy. Progression into
the afferent ileal limb should always be attempted.
Endoscopic findings compatible with pouchitis include
diffuse erythema, which may be patchy, unlike that
observed in UC. Characteristic endoscopic findings also
include oedema, granularity, friability, spontaneous or
contact bleeding, loss of vascular pattern, mucous exudates,
haemorrhage, erosions and ulceration.17 Erosions and/or
ulcers along the staple line do not necessarily indicate
pouchitis.18,22,23 Biopsies should be taken from the pouch
mucosa and from the afferent limb above the pouch, but not
along the staple line.
8.1.3. Histopathology of pouchitis
Histological findings of pouchitis are also non-specific,
including acute inflammation with polymorphonuclear leu-
kocyte infiltration, crypt abscesses and ulceration, in
association with a chronic inflammatory infiltrate.22,23
There may be discrepancy between endoscopic and histo-
logic findings in pouchitis, possibly related to sampling
error.24,25 Morphological changes of the epithelium lining
the ileal pouch normally develop in the 12–18 months after
ileostomy closure, characterised by flattening and a reduced
number, or complete disappearance of the villi, leading to
villous atrophy (“colonic metaplasia”).23–25 Although the
aetiology of pouchitis remains unknown, it can be inferred
from the predeliction for patients with UC and the response
to antibiotic therapy that the bacterial flora and/or other
triggers of inflammation in UC are involved.26,27 Pouchitis
tends to occur only after colonic metaplasia has developed
in the pouch, although a causal association is unproven.
Statement 8B
The most frequent symptoms of pouchitis are
increased number of liquid stools, urgency, abdom-
inal cramping and pelvic discomfort. Fever and
bleeding are rare [EL1c, RGB]. Routine pouchoscopy
after clinical remission is not required [EL5, RG D]
8.1.4. Differential diagnosis
The clinical history and biopsies help discriminate between
pouchitis, ischaemia, Crohn's disease (CD) and other rare
forms of pouch dysfunction such as collagenous pouchitis,
Clostridium difficile or cytomegalovirus pouchitis.28–30
Secondary pouchitis, caused by pelvic sepsis, usually causes
focal inflammation and should be considered. Biopsies taken
from the ileum above the pouch may reveal pre-pouch ileitis
as a cause of pouch dysfunction, although this usually causes
visible ulceration that may be confused with Crohn's
disease.31 The possibility of non-specific ileitis caused by
NSAIDs should be considered.32
4 G. Van Assche et al.8.1.5. Risk factors for pouchitis and pouch dysfunction
The aetiology of pouchitis remains unclear. Risk factors,
genetic associations, and serological markers of pouchitis
suggest that a close interaction between the host immune
response and the pouch microbiota plays a relevant role in the
aetiology of this idiopathic inflammatory condition.33
Reported risk factors for pouchitis include extensive UC,1,34
backwash ileitis,34 extraintestinal manifestations (especially
primary sclerosing cholangitis),5,19,35 being a non-smoker36
and regular use of NSAIDs.32,37 Interleukin-1 receptor antag-
onist gene polymorphisms38 and the presence of perinuclear
neutrophil cytoplasmic antibodies39 are also associated with
pouchitis. Not surprisingly studies are discordant with regard
to the role of each risk factor. Some of the best data on risk
factors come from the Cleveland Clinic.40 Two hundred and
forty consecutive patients were classified as having healthy
pouches (n=49), pouchitis (n=61), Crohn's disease (n=39),
cuffitis (n=41), or irritable pouch syndrome (n=50). The risk
of developing pouchitis was increased when the indication for
IPAA was dysplasia (OR 3.89; 95% CI 1.69–8.98), when the
patient had never smoked (OR 5.09; 95% CI 1.01–25.69), used
NSAIDs (OR 3.24; 95% CI 1.71–6.13), or (perhaps surprisingly)
had never used anxiolytics (OR 5.19; 95% CI 1.45–18.59). The
risk of a diagnosis of Crohn's disease in the pouch was greatly
increased by being a current smoker (OR 4.77; 95% CI, 1.39–
16.25), and modestly increased with having a pouch of long
duration (OR 1.20; 95% CI 1.12–1.30). Cuffitis was associated
with symptoms of arthralgia (OR 4.13; 95% CI 1.91–8.94) and a
younger age (OR 1.16; 95% CI 1.01–1.33). Irritable pouch
syndrome is probably under-recognised, although is a common
cause of pouch dysfunction when other causes (including a
small volume pouch, incomplete evacuation and pouch
volvulus) have been excluded and investigations are normal.
The principal risk factor is the use of antidepressants (OR 4.17;
95% CI 1.95–8.92) or anxiolytics (OR 3.21; 95% CI 1.34–7.47),
which suggests that these peoplemay have had irritable bowel
syndrome contributing to symptoms of colitis before pouch
surgery.40 Similar to irritable bowel syndrome, a visceral
hypersensitivity has been described in these patients.41 The
same group has recently shown that various perioperative
factors may predict pouchitis. On multivariate analysis,
pulmonary comorbidity, disease proximal to the splenic
flexure, extraintestinal manifestations, and S-pouch recon-
struction were associated with pouchitis.42 These risk factors
should not preclude proctocolectomy if surgery is appropriate,
but should be included pre-operative discussions with the
patient and family. If there is a disparity between preopera-
tive and endoscopic appearance, or if the patient is on
antidepressants, then the risk of pouch dysfunction after IPAA
needs particularly careful consideration. Similarly, if a patient
has primary sclerosing cholangitis, then it is appropriate to
discuss the higher risk of pouchitis. These discussions are part
of appropriate management of expectations and known
predictive factors for pouchitis or irritable pouch should not
be considered as formal contraindications for pouch surgery.Statement 8C
The majority of patients respond to metronidazole
or ciprofloxacin, although the optimummodality of8.2. Pattern of pouchitis
8.2.1. Acute and chronic pouchitis
On the basis of symptoms and endoscopy, pouchitis can
be divided into remission (normal pouch frequency) or activepouchitis (increased frequency with endoscopic appearances
and histology consistent with pouchitis).15,43 Active
pouchitis may then be divided into acute or chronic,
depending on the symptom duration. The threshold for
chronicity is a symptom duration of N4 weeks. Up to 10% of
patients develop chronic pouchitis requiring long-term
treatment, and a small subgroup has pouchitis refractory to
medical treatment.3 From various perspectives pouchitis
may also be classified into: 1) idiopathic versus secondary, 2)
in remission versus active, 3) infrequent (b3 episodes per
year) versus relapsing (N3 episodes per year). Pouchitis may
also be classified based on the response to antibiotic
therapy: 1) antibiotic-responsive, 2) antibiotic-dependent
(need for continuous antibiotic treatment to maintain
remission), 3) antibiotic-refractory.44
8.2.2. Scoring of pouchitis
The Pouchitis Disease Activity Index (PDAI) has been
developed to standardise diagnostic criteria and assess the
severity of pouchitis.15,43,45 The PDAI is a composite score that
evaluates symptoms, endoscopy and histology. Each compo-
nent of the score has a maximum of 6 points. Patients with a
total PDAI score≥7 are classified as having pouchitis although
a patient should exhibit both clinical symptoms and endo-
scopic or histological evidence of pouchitis. The problem is
that about a quarter of patients with a high symptom score
suggestive of pouchitis may not fulfil criteria for the diagnosis
of pouchitis, as assessed by the PDAI, since endoscopic or
histological criteria may be absent. Consequently a relatively
large number of patients may be unnecessarily treated for
pouchitis when symptoms are due to other conditions. Other
scoring systems have been devised, including the Moskowitz
index22 and an index from Heidelberg. Comparisons with the
PDAI46,47 show that they are not interchangeable, but this
affects clinical trials rather than clinical practice.
8.2.3. Recurrent pouchitis and complications
Pouchitis recurs in more than 50% patients.3,15,41 Patients
with recurrent pouchitis can broadly be grouped into three
categories: infrequent episodes (b1/year), a relapsing course
(1–3 episodes/year) or a continuous course. Pouchitis may
further be termed treatment responsive or refractory, based on
response to antibiotic mono-therapy7,9 (see Section 1.3.2).
Although these distinctions are largely arbitrary, they help both
patients and their physicians when considering management
options to alter the pattern of pouchitis. Complications of
pouchitis include abscesses, fistulae, stenosis of the pouch-anal
anastomosis and adenocarcinoma of the pouch.7,28,43 The latter
complication is exceptional and almost only occurs when there
is pre-exiting dysplasia or carcinoma in the original colectomy
specimen.
8.3. Medical treatment
8.3.1. Acute pouchitis: antibiotics
treatment is not clearly defined [EL1b, RG B]. Side
effects are less frequent using ciprofloxacin [EL1c,
RG B]. Antidiarrhoeal drugsmay reduce the number
of daily liquid stools in patients, independent of
pouchitis [EL5, RG D]
5Second European evidence-based consensus on ulcerative colitis' diagnosis and managementTreatment of pouchitis is largely empirical and only small
placebo-controlled trials have been conducted. Antibiotics
are the mainstay of treatment, and metronidazole and
ciprofloxacin are the most common initial approaches,
often resulting in a rapid response. The odds ratio of inducing
response using oral metronidazole compared with placebo
in active chronic pouchitis is 26.67 (95% CI 2.31–308.01,
NNT=2).48 However, randomised trials of both metronida-
zole and ciprofloxacin are small.3,49 The two have been
compared in another small randomised trial50 Seven patients
received ciprofloxacin 1 g/day and nine patients metronida-
zole 20 mg/kg/day for a period of 2 weeks. Ciprofloxacin
lowered the PDAI score from 10.1±2.3 to 3.3±1.7 (p=
0.0001), whereas metronidazole reduced the PDAI score
from 9.7±2.3 to 5.8±1.7 (p=0.0002). There was a signifi-
cantly greater benefit with ciprofloxacin compared to
metronidazole in terms of the total PDAI (p=0.002),
symptom score (p=0.03) and endoscopic score (p=0.03), as
well as fewer adverse events (33% of metronidazole-treated
patients reported side-effects, but none on ciprofloxacin).
The treatment and prevention of pouchitis has been
systematically reviewed in 2010 by a Cochrane analysis. For
the treatment of acute pouchitis (4 RCTS, 5 agents)
ciprofloxacin was more effective at inducing remission than
metronidazole. Neither rifaximin nor Lactobacillus plantarum
GG were more effective than placebo, while budesonide
enemas andmetronidazole were equally effective for inducing
remission. In a non-randomised, non-controlled, open-label
trial, a highly concentrated probiotic preparation (VSL#3) was
shown to be effective in the treatment of mildly active
pouchitis.51
8.3.2. Chronic pouchitis: combination antibiotic therapy
or budesonide
Statement 8D
In chronic pouchitis a combination of two antibi-
otics is effective [EL1b, RG B]. Oral budesonide is
an alternative [EL2b, RG B]. Infliximab is effective
for the treatment of chronic refractory pouchitis
[EL4, RG C]
For patients who have persistent symptoms, alternative
diagnoses should be considered, including undiagnosed
Crohn's disease, pouch-anal or ileal-pouch stricture, infec-
tion with CMV or Cl difficile, collagenous pouchitis, cuffitis,
anatomical disorders, or irritable pouch syndrome. Approx-
imately 10–15% of patients with acute pouchitis develop
chronic pouchitis, which may be “treatment responsive”
or “treatment refractory” to single antibiotic therapy.45Patients with chronic, refractory pouchitis do not respond to
conventional therapy and often have ongoing symptoms.
This is a common cause of pouch failure. Combination
antibiotic therapy or oral budesonide may be effective.
Sixteen consecutive patients with chronic, refractory
pouchitis (disease N4 weeks and failure to respond to
N4 weeks of single-antibiotic therapy) were treated with
ciprofloxacin 1 g/day and tinidazole 15 mg/kg/day for
4 weeks.52 A historic cohort of ten consecutive patients with
chronic refractory pouchitis treated with high dose oral and
topical mesalazine daily was used as a comparator. These
treatment-refractory patients had a significant reduction in the
total PDAI score and a significant improvement in quality-of-life
score (pb0.002) when taking ciprofloxacin and tinidazole,
compared to baseline. The rate of clinical remission in the
antibiotic group was 87.5% and for the mesalazine group was
50%.
In another study, 18 patients refractory to metronidazole,
ciprofloxacin or amoxicillin/clavulanic acid for 4 weeks were
treated orally with rifaximin 2 g/day (a nonabsorbable, broad
spectrum antibiotic) and ciprofloxacin 1 g/day for 15 days.
Sixteen out of 18 patients (88.8%) either improved (n=10) or
went into remission (n=6).53 Median PDAI scores before and
after therapy were 11 (range 9–17) and 4 (range 0–16),
respectively (pb0.002). A British group observed similar
benefit in just 8 patients.54 In another combination study, 44
patients with refractory pouchitis received metronidazole
800 mg–1 g/day and ciprofloxacin 1 g/day for 28 days.55
Thirty-six patients (82%) went into remission and median
PDAI scores before and after therapy were 12 and 3
respectively (pb0.0001). The alternative is oral budesonide
CIR 9 mg daily for 8 weeks, which achieved remission in 15/20
(75%) patients not responding after 1 month of ciprofloxacin
or metronidazole.56 Oral budesonide also appears to have no
impact on liver function tests in pouchitis patients with PSC,
while improving significantly the pouch and afferent limb
inflammation.57 The cumulative data (derived mainly from
underpowered trials) suggest that, if ciprofloxacin does not
work, it should be tried in combination with an imidazole
antibiotic or rifaximin, with an alternative being oral
budesonide.
8.3.3. Acute and chronic refractory pouchitis:
other agents
A variety of approaches has been assessed in open label
and small controlled trials. Budesonide enemas were as
effective as metronidazole for acute pouchitis in a
randomised controlled trial.58 Ciclosporin enemas were
successful for chronic pouchitis in a pilot study59 and oral
azathioprinemay help if patients relapse become budesonide-
dependent. Uncontrolled studies of short-chain fatty acid
enemas and suppositories.60–62 Of more interest, infliximab
has been tried in patients with chronic, refractory pouchitis.63
A series of 28 patients with an IPAA who had developed
refractory pouchitis were treated with infliximab. Patients
had either pouchitis/pre-pouch ileitis (n=25) and/or pouch
fistula (n=7) (patients with evidence of known Crohn's disease
were excluded). 82% of patients received concomitant
immunomodulator therapy. After 10 weeks of therapy 88% of
treated patients showed a clinical response (14 partial,
8 complete) and 6/7 patients with a fistula improved (3
partial, 3 complete). PDAI decreased from 9.0 to 4.5 points. In
6 G. Van Assche et al.addition, clinical responses after a median follow-up of
20 months were observed in 56% patients. Five patients
needed permanent ileostomy.63 The effect of infliximab
in ten patients with chronic refractory pouchitis com-
plicated by ileitis has also been described64; 9/10 patients
achieved clinical remission and 8/10 demonstrated com-
plete recovery of endoscopic lesions which was maintained
for at least 6 months. More recently, in a multicentre
Spanish retrospective study, 33 patients with chronic
refractory pouchitis were treated with infliximab. 21%,
33% and 27% achieved complete response at week 8, 26
and 52.65 Although infliximab might be an effective
long-term therapy for pouchitis, clinical data are still
few and prospective, multicentre, randomised controlled
trials are needed. A possible alternative for patients with
chronic refractory pouchitis previously treated with
infliximab may be adalimumab; 50% of patients avoided
a permanent ileostomy after 1 year of treatment with
adalimumab.66
Finally, benefit has been reported from alicaforsen enemas
(an inhibitor of intercellular adhesionmolecule (ICAM)-1) in an
open-label trial. Twelve patients with chronic refractory
pouchitis were treated with 240 mg enemas and 7/12 (58%)
were in remission after 6 weeks.678.3.4. Maintenance of remission: probiotics
Statement 8E
Probiotic therapywith VSL#3 (18×1011 of 8 bacterial
strains for 9 or 12 months) has shown efficacy for
maintaining antibiotic-induced remission [EL1b, RG
B]. VSL#3 (9×1011 bacteria) has also shown efficacy
for preventing pouchitis [EL2b, RG C]Once remission has been obtained in chronic pouchitis,
treatment with the concentrated probiotic mixture VSL#3
helps maintain remission. Two double-blind, placebo-
controlled studies have shown the efficacy of VSL#3 (450
billion bacteria of 8 different strains/g) to maintain remission
in patients with chronic pouchitis. In the first study, 40
patients who achieved clinical and endoscopic remission
after 1 month of combined antibiotic treatment (rifaximin
2 g/day+ciprofloxacin 1 g/day), were randomised to receive
either VSL#3, 6 g/day (18×1011 bacteria/day), or placebo for
9 months.68 All 20 patients who received placebo relapsed,
while 17/20 patients (85%) treated with VSL#3 remained
in clinical and endoscopic remission at the end of the study.
Interestingly, all 17 patients relapsed within 4 months of
stopping VSL#3. In the second study, 36 patients with chronic,
refractory pouchitis who achieved remission (PDAI=0) after
1 month of combined antibiotic treatment (metronidazole+
ciprofloxacin) received 6 g/once a day of VSL#3 or placebo
for 1 year. Remission rates at 1 year were 85% in the VSL#3
group and 6% in the placebo group (pb0.001).69 In the
Cochrane systematic review VSL#3 was more effective than
placebo in maintaining remission of chronic pouchitis in
patients who achieved remission with antibiotics.518.3.5. Prevention of pouchitis: probiotics
The same probiotic preparation (VSL#3) has been shown
to prevent pouchitis within the first year after surgery in a
randomised, double-blind, placebo-controlled study. Forty
consecutive patients undergoing IPAA for UC were
randomised within a week of ileostomy closure to VSL#3
3 g (9×1011) per day or placebo for 12 months. Patients
were assessed clinically, endoscopically and histologically at
1, 3, 6, 9 and 12 months. Patients treated with VSL#3 had a
significantly lower incidence of acute pouchitis (10%)
compared with those treated with placebo (40%) (pb0.05),
and experienced a significant improvement of quality of
life.70 A Cochrane systematic review reports that VSL#3 was
more effective than placebo for the prevention of
pouchitis.51 The mechanism of action of probiotic therapy
remains elusive.71 Patients who develop pouchitis have low
bacterial and high fungal diversity in the mucosa-associated
pouch microbiota. Bacterial diversity was increased and
fungal diversity was reduced in patients in whom remission
was maintained using VSL#3 (p=0.001). VSL#3 increased the
total number of bacterial cells assessed by real time PCR (p=
0.002) and modified the spectrum of bacteria towards
anaerobic species. Taxa-specific clone libraries showed
that the spectrum of Lactobacillus sp. and Bifidobacter sp.
was altered by probiotic therapy. The diversity of the fungal
flora was repressed. Restoration of the integrity of a
“protective” intestinal mucosa related microbiota could
therefore be one mechanism by which probiotic bacteria
work.
8.4. Cuffitis
Statement 8F
Rectal cuff inflammation (cuffitis) may induce
symptoms similar to pouchitis or irritable pouch
syndrome, although bleeding is more frequent
[EL2a, RG B]. Topical 5-ASA has shown efficacy
[EL4, RGD]
Cuffitis can cause pouch dysfunction with symptoms that
mimic pouchitis or irritable pouch syndrome (IPS) especially
after double-stapled IPAA (see Section 7). Unlike IPS
(which may coexist) bleeding is a characteristic feature of
cuffitis. Endoscopy is diagnostic, but care has to be taken to
examine the cuff of columnar epithelium between the
dentate line and pouch-anal anastomosis (Section 7.2.3).72
In an open-label trial, 14 consecutive patients with cuffitis
treated with mesalazine suppositories 500 mg twice
daily experienced a reduction in the total Cuffitis Activity
Index (derived from the PDAI) from 11.9+3.17 to 6.21+3.19
(pb0.001).16 In addition the symptom subscore reduced
from 3.24±1.28 to 1.79±1.31, endoscopy subscore from
3.14±1.29 to 1.00±1.52 and histology subscore from 4.93±
1.77 to 3.57±1.39. 92% of patients with bloody bowel
movements and 70% with arthralgia (a characteristic
clinical feature of cuffitis (Section 1.1.4)) improved on
therapy. No systemic or topical adverse effects were
reported.
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9.1. Risk of colorectal cancer in UC
Statement 9A
Patients with longstanding ulcerative colitis have
an increased risk of colorectal cancer compared
to the general population [EL 1b, RG B]Although it is generally accepted that longstanding
ulcerative colitis is associated with an increased risk of
colorectal carcinoma (CRC), the reported risk estimates
vary widely. In 2001, Eaden published a frequently cited
meta-analysis of 116 studies dating from 1935 to 1999.73
Based on 19 of these 116 studies, cumulative risks up to
18% at 30 years of disease duration were found. Older
studies, which often originate from referral centres, even
report cumulative risks up to 43%,74 while risks in newer,
population-based studies seem to be hardly increased
as compared to the general population.75–77 These
differences have been attributed to differences in study
design, study population and patient selection. The risks
of CRC seem to decline over time as well, as highlighted
in a study from St. Marks.78 This might reflect an increased
implementation of surveillance strategies, introduction
of drugs that control inflammation more effectively, or
a changing approach to maintenance therapy or colec-
tomy. Hence, it seems that patients with longstanding
ulcerative colitis carry an increased risk of developing
CRC, but this risk is probably not as high as previously
perceived.
Statement 9B
The risk of colorectal cancer in ulcerative colitis is
associated with disease duration and extent [EL
1b, RG B]
In the Eaden meta-analysis, cumulative CRC risks of 2% at
10 years, 8% at 20 years and 18% at 30 years disease duration
were reported. Although it has been stated that CRC is rarely
encountered when disease duration is less than 8 years, a
significant number of tumours might develop within this
time window,76,79 especially in patients who are older at
colitis onset. Whether these early CRC cases are truly
colitis-associated or sporadic carcinomas cannot be deter-
mined from these studies. The role of disease extent with
regard to the CRC risk is undisputed. Patients with pancolitis
or colitis extending proximal to the splenic flecture carry
the highest risks, and patients with a left sided colitis having
an intermediate risk profile. CRC risk is not increased
in patients with UC limited to the rectum.73 Of note,
histological extent, even without endoscopically visible
abnormalities, may be an important determinant of the
cancer risk as well.80Statement 9C
Concomitant Primary Sclerosing Cholangitis (PSC),
post-inflammatory polyps, a family history of CRC
and more severe or persistent inflammatory
activity confer an additional risk for CRC in
ulcerative colitis patients [EL 1b, RG B]
The wide variation of risk estimates reported in literature
may be attributed to differences in additional risk factors in
the patient cohorts studied. The most consistent risk factors
reported are primary sclerosing cholangitis (PSC) with a CRC
risk up to 31%81–83and histological or clinical disease
activity.84–86 Post-inflammatory polyps may be markers of
previous inflammatory severity and have also been found to
be strong risk factors.75,84,87 However it is possible that this
increased risk relates to missed dysplastic lesions mistakenly
diagnosed as post-inflammatory polyps. Early onset of
disease before the age of 20–25 years may also contribute
to an increased risk, although it cannot be distinguished
from the published data whether this is a truly independent
risk factor or solely explained by disease duration.76,77,88 A
family history of CRC is associated with an increased risk,
although not consistently so across the studies.82,899.2. Surveillance issues
9.2.1. Screening and surveillance
Since dysplastic change in colonic mucosa is associated with
an increased risk of colorectal cancer (CRC) in ulcerative colitis
(UC), surveillance colonoscopy programmes have been devel-
oped with the aim of reducing morbidity and mortality due
to CRC, while avoiding unnecessary prophylactic colectomy.
Surveillance for CRC in patients with UC involves not only
performing repeated colonoscopies, but includes reviewing the
patient's symptoms, medications and laboratory test results, as
well as updating personal and family medical history. At the
onset of these programmes, an initial screening colonoscopy
is performed, with the goal of reassessing disease extent
and confirming the absence of dysplastic lesions. Thereafter
surveillance colonoscopies are regularly performed at defined
intervals.
9.2.2. Effectiveness
Statement 9D
Regular follow-up colonoscopies could be carried
out, because surveillance colonoscopy may per-
mit earlier detection of CRC, with a corresponding
improved prognosis [EL 3a, RG B]
Randomised controlled trials have not been performed to
prove whether surveillance colonoscopy is effective. How-
ever, a large number of case series have suggested a benefit
of surveillance colonoscopy.90–94 In a retrospective study of
out 6–8 years after the beginning of symptoms in
order to assess the patient's individual risk profile
[EL 5, RG D]
8 G. Van Assche et al.40 patients with UC associated CRC, Giardiello reported that
the CRC was detected at a statistically significantly earlier
stage when patients were diagnosed in a surveillance
programme (Dukes A/B: 67% vs. 9%).95
Three case–control studies have addressed this issue. In a
population-based, nested case–control study of 142 patients
with UC (derived from a study population of 4664 patients) from
Stockholm, Sweden, 2 of 40 patients with UC and CRC and 18 of
102 controls had undergone at least one surveillance colonos-
copy (RR, 0.29; 95% CI, 0.06–1.31). Twelve controls, but only
one patient with UC-CRC, had undergone 2 ormore surveillance
colonoscopies (RR, 0.22; 95% CI, 0.03–1.74). Although not
statistically significant, the investigators suggested that fre-
quent colonoscopy protects against CRC.96 In 1990 Lashner et
al. reported that 4 of 91 patients who underwent surveillance
died of CRC, as compared to 2 of 95 patients who did not
undergo surveillance (RR, 2.09; 95% CI, 0.39–11.12). Colectomy
was less common in the surveillance group (33 vs. 51; pb0.05).
It was performed, on average, 4 years later (after 10 years of
disease) in the surveillance group.97 Finally, Choi et al.
examined 41 patients who developed CRC between 1974 and
1991.98 In this outcome study, 19 patients who underwent
colonoscopic surveillance presented with a significantly earlier
stage of cancer compared to 22 patients who did not participate
in a colonoscopic surveillance programme (p=0.039). The
5-year survival rate was 77.2% in the surveillance group and
36.3% in the non-surveillance group.
In the Cochrane pooled data analysis of these 3 studies, 8 of
110 patients in the surveillance group died of CRC compared to
13 of 117 patients in the non-surveillance group (RR, 0.81; 95%
CI, 0.17–3.83).99The Cochrane analysis concluded the follow-
ing: ‘there is no clear evidence that surveillance colonoscopy
prolongs survival in patients with extensive colitis. There is
evidence that cancers tend to be detected at an earlier stage in
patients who are undergoing surveillance, and these patients
have a correspondingly better prognosis, but lead-time bias
may contribute substantially to this apparent benefit. There is
indirect evidence that surveillance is likely to be effective at
reducing the risk of death from IBD-associated CRC and indirect
evidence that it may be acceptably cost-effective99.
More recently, in a study from the Netherlands a total of
149 patients with IBD-associated CRC were identified.100
Twenty-three had colonoscopic surveillance before CRC was
discovered. The 5-year CRC-related survival rate of patients in
the surveillance group was 100% compared with 74% in the
non-surveillance group (p=0.042). In the surveillance group,
only one patient died as a consequence of CRC compared with
29 patients in the control group (p=0.047). In addition, more
early tumour stages were found in the surveillance group (p=
0.004). These results provide evidence for improved survival
from colonoscopic surveillance in IBD patients by detecting
CRC at a more favourable tumour stage.9.2.3. Initial screening colonoscopy and surveillance
schedulesStatement 9E
In all patients with UC irrespective of the disease
activity, a screening colonoscopy could be carriedStatement 9F
When disease activity is limited to the rectum
without evidence of previous or current endo-
scopic and/or microscopic inflammation proximal
to the rectum, inclusion in a regular surveillance
colonoscopy programme is not necessary [EL2a,
RG B]
Statement 9G
In cases with concurrent primary sclerosing
cholangitis (PSC), surveillance colonoscopies
should be carried out yearly from the point of
PSC diagnosis irrespective of disease activity and
extent [EL3a, RG B]
Statement 9H
The CRC risk profile should be determined at the
screening colonoscopy or the first surveillance
colonoscopy 6 to 8 years after the first manifesta-
tion. Risk stratification mainly depends on extent
of disease, severity endoscopic and/or histological
inflammation, pseudopolyps, concurrence of PSC,
and family history of CRC [EL2b, RG B]
Statement 9I
The individual risk profile dictates surveillance
colonoscopy intervals: every 1–2 years (high-risk)
or every 3–4 years (low-risk) from the eighth year
after the first manifestation in both extensive UC
and left-sided UC [EL5, RG D]
The CRC risk profile can be determined at the screening
colonoscopy or at the first surveillance colonoscopy 8 years
after disease onset. Risk stratification mainly depends on
four items (e.g. each of these items to be counted with one
point): Pancolitis, endoscopic and/or histological inflamma-
tion, pseudopolyps and family history of CRC (low-risk 0–2
and high-risk 3–4 points). Ongoing surveillance colonoscopy
should be carried out based on the individual risk profile
either every 1–2 years (high-risk) or every 3–4 years
otherwise difficult to discriminate between dys-
plasia and inflammation on mucosal biopsies [EL5,
RG D]
9Second European evidence-based consensus on ulcerative colitis' diagnosis and management(low-risk) from the eighth year after the disease onset in
cases of extensive UC as well as in cases of left-sided UC. If
there is no evidence of IEN or endoscopic and/or histological
inflammation in two consecutive surveillance colonoscopies
the surveillance interval may be increased (e.g. from every
1–2 years to every 3–4 years).
A meta-analysis suggests that follow-up colonoscopies may
reduce the risk of dying of a colitis-associated colon carcinoma
and are cost-effective. This is based on the fact that
colitis-associated colon carcinomas are recognised earlier,
although interval carcinomas may occur, nonetheless.99
The risk of developing a carcinoma increases with the
duration of disease and the disease extent, therefore regular
monitoring should start earlier in the case of pancolitis than
left-sided or distal colitis. Of note, a Dutch study recently
pointed out that up to 22% of patients that develop a
colitis-associated colon carcinoma do so prior to commenc-
ing surveillance colonoscopies.79 If patients suffering from
PSC are excluded – as they should be monitored from the
time of PSC diagnosis – the carcinomas “missed” are
reduced to approximately 15%. Considering this and knowing
that a pancolitis may develop from inflammation described
initially as a distal colitis without overt clinical symptoms, a
full colonoscopy with multiple biopsies should be carried out
within 6–8 years after the first symptoms of disease in order
to establish the endoscopic and/or microscopic extent of
disease and to pace subsequent endoscopic surveillance.
The monitoring interval should vary from 1 to 4 years
according to the individual risk profile to prevent the
development of interval carcinomas.93,101,102 As the risk for
CRC is only minimally increased in patients with proctitis (with
no other risk factors), no regular monitoring is required in this
group. In contrast, the risk of developing a carcinoma in
patients with ulcerative colitis and PSC is not only five times
higher,103 but has been reported to occur early (median
2.9 years) in the course of the disease104 with carcinomas
frequently occurring on the right-hand side of the colon.105
Therefore, patients should be monitored annually from the
diagnosis. After sub-total colectomy with an ileorectal anasto-
mosis or restorative proctocolectomy, carcinomas may occur in
the remaining colonic mucosa distally to the anastomosis or
within the pouch.106 Therefore, the remaining colon and/or the
pouch should be monitored at regular intervals.
9.3. Colonoscopic procedures
Statement 9J
Good bowel preparation is essential for effective
surveillance colonoscopy. If faecal residue is
present, repeat colonoscopy should be consid-
ered [EL5, RG D]Statement 9K
Colonoscopic surveillance is best performed when
ulcerative colitis is in remission, because it isSurveillance colonoscopies aim to detect neoplasia with a
high sensitivity and specificity. If possible, surveillance
colonoscopies should be carried out in remission, because
remaining inflammatory activity could be misinterpreted as
intra-epithelial neoplasia. Similar to screening colonosco-
pies in the otherwise healthy population, the quality of the
preparation will significantly affect the detection rate of
lesions.107 In addition, there is a correlation between the
withdrawal time and the detection rate of neoplasias.108
Statement 9L
Chromoendoscopy with targeted biopsies is the
surveillance procedure of choice for appropriately
trained endoscopists [EL1b, RG B]. Alternatively,
random biopsies (quadrant biopsies every 10 cm)
and targeted biopsies of any visible lesion should
be performed if white light endoscopy is used
[EL3, RG B]Several studies performed during the last few years have
demonstrated that most intraepithelial neoplasias (IEN) can
be visualised by high-resolution endoscopy, either as irregular
mucosa, strictures or mucous membrane elevations109–111
Therefore, it is very important to take targeted biopsies from
all visible suspicious lesions. In addition, in order to assess
disease extent and mucosal healing it is useful to take 2
biopsies from each colonic segment. Using white light
colonoscopy alone, IEN may not be visible macroscopically
(about 20%): Rubin et al. were able to demonstrate in a
mathematical model that at least 34 “blind” biopsies are
required to achieve a 90% confidence interval for detection of
carcinomas with 64 biopsies reaching a 95% confidence
interval.112 Therefore, we recommend taking four biopsies
every 10 cm in order to achieve a 90% certainty of detection,
although chromoendoscopy by an appropriately trained
endoscopist is the preferred procedure.
Using mathematical modelling Awais113 calculated the
confidence level with which dysplasia can be excluded, the
dysplastic field size detection threshold, the predicted area
of a dysplastic field, and the number of biopsies needed for a
given dysplasia detection threshold and confidence level. In
this model, 32 random biopsies provide only 80% confidence
that dysplasia involving≥5% of the colon can be detected. In
order to have 90% confidence of achieving a dysplasia
detection threshold equal to enhanced endoscopy (10 mm
diameter circle with an area of 0.785 cm2) 4690 random
biopsies are required. When one single biopsy out of 18 is
dysplastic, this predicts a dysplastic area (89 cm2) several
orders of magnitude greater than dysplastic fields that are
readily detectable by enhanced endoscopy (1 cm diameter),
and the predicted field size increases rapidly with multiple
positive biopsies.
10 G. Van Assche et al.The enhanced ability to detect IEN with high-resolution
endoscopy makes the strategy of taking random biopsies
controversial. Furthermore, a survey on the implementation
of the recommendation of 40–50 random biopsies in surveil-
lance colonoscopies in Germany revealed that only 9.2% of
the surveillance colonoscopies were performed in accordance
with the guidelines.114 The same issue with adherence to
surveillance guidelines has been reported in several other
countries.115–117 The futility of taking random biopsies is
also highlighted by the fact that IEN was detected by random
biopsy extremely rarely in studies comparing conventional
colonoscopy with chromoendoscopy (Kiesslich 2003: 2 IEN in
5,098 random biopsies,118 Rutter 2004: 0 IEN in 2,906 random
biopsies119 and Dekker 2007: 1 IEN in 1,522 random biopies120).
The preferred alternative is to perform chromoendoscopy
(indigo carmine or methylene blue) with targeted biopsies. In
two prospective, single centre studies more IEN was discovered
with biopsies using chromoendoscopy than by white light
endoscopy.118,119 Furthermore Hurlstone121 reported, that
high-magnification, indigo carmine-assisted chromoendoscopy
can improve the detection of intraepithelial neoplasia in the
endoscopic screening of patients with ulcerative colitis.
The value of high-resolution virtual chromoendoscopy
(NBI, FICE, iScan) with targeted biopsies has not been
sufficiently resolved.120 Therefore this should not be used
as the surveillance strategy. Nevertheless, it is still unclear
how much technical experience is required to perform
adequate chromoendoscopy and whether the latest gener-
ation of endoscope combining HDI and/or HDTV will permit a
similarly high IEN detection rate.9.4. Chemoprevention
9.4.1. 5-ASA and CRC
Chemopreventive agents are used to inhibit, delay or
reverse carcinogenesis. 5-Aminosalicylates (5-ASA) are
considered to reduce the risk of colorectal cancer in patients
with UC in cohort and case–control studies. A randomised
controlled trial specifically designed to confirm this effect is
not feasible given the prohibitive number of patients at risk
that would need to be enrolled in each arm (1000 to 3000
according to base-case cancer incidences78 and projected risk
reduction (30 to 50%)). In themeta-analysis by Velayos et al., 3
cohort studies122–124 and 6 case–control studies pub-
lished84,93,125,126 or presented127 up to January 2004 were
reviewed.87 The risk of CRC was halved in patients exposed to
5-ASA and this reduction was statistically significant (OR 0.51,
95% CI 0.37–0.69). Seven studies have been fully published
thereafter.82,86,127–130 However, four of them do not differ-
entiate the risk of CRC from that of other forms of advanced
dysplasia (CRC and high-grade dysplasia)82 or all forms of
dysplasia.86,87,127 In 2006 Velayos assessed the risk factors for
188 cases of CRC (in patients with UC seen at the Mayo Clinic
from 1976 to 2002).87 In the final multivariate model a
significant reduction in the risk of CRC associated with an
exposure to 5-ASA of at least 1 year (OR 0.4, 95% CI 0.2–0.9)
was confirmed. Two further studies were based on the number
of 5-ASA prescriptions in large Health Care databases.128,129
van Staa et al. suggested from the GPRD database that a
regular use of 5-ASA within the year preceding the diagnosis of
CRC was associated with a significant reduction in the risk.Similarly, Terdiman et al. found a trend (p=0.08) toward a
decreased risk of CRC with increasing number of 5-ASA
prescriptions within the year preceding the diagnosis of CRC.
However, Bernstein et al. have updated the negative case–
control study from the Manitoba database126 and still found no
favourable effect of 5-ASA. Of note, in this cohort, the disease
extent was not reported and the updated analysis was not
adjusted for the propensity to receive 5-ASA (although this
treatment has probably been specifically prescribed in
patients at highest risk of CRC for the purpose of chemopre-
vention in the last few years). In conclusion, when updating
the literature, there is no definite reason to challenge the
previous statement that 5-ASA may reduce the incidence of
CRC in patients with UC.131
9.4.2. Patient selection for chemoprevention with 5-ASA
Besides an individual context (such as PSC or a family
history of CRC) that may justify endoscopic surveillance and
chemoprevention from diagnosis131–134; the three main
determinants of excess risk of CRC in patients with UC are
the duration of the disease, the cumulative extent of the
disease at any time and chronic macroscopic110 and micro-
scopic80,85 inflammation of the colonic mucosa.131–134 The
question whether the protective effect of 5-ASA on the CRC
risk is different in patients with known risk factors for
dysplasia or cancer has not been addressed in the literature.
In a case–control study nested in the CESAME cohort,
adjusted for the propensity of receiving 5-ASA, a subanalysis
was performed in IBD patients with or without longstanding
(N10 years) extensive (N50% of colonic mucosa at any time)
colitis.135 The protective odds-ratio was significant for
patients with longstanding extensive colitis (OR 0.5, 95% CI
0.2–0.9) while it was not in the remaining patients (OR 0.8,
95% CI 0.3–1.7). However, the published statements on the
chemopreventive effect of 5-ASA in UC are not restricted to
particular situations (such as longstanding and/or extensive
colitis),131–133 which justifies lifelong chemoprevention from
diagnosis in all patients, except for those ongoing isolated
proctitis. Many arguments can be listed for legitimating
this position: first, a significant proportion of CRC are
diagnosed within the first years after the diagnosis, even if
a significant proportion of them are likely to be sporadic
cases; second, it is established that carcinogenesis of
sporadic and inflammation-related CRC is quite differ-
ent,134,136 but given the multiplicity of potential molecular
mechanisms of action of 5-ASA on carcinogenesis,137 it is
theoretically possible that 5-ASA may have a chemopreven-
tive effect in sporadic CRC as well as in inflammation-driven
cancers; third, inflammation appears as an independent
important driver for UC-related CRC,80,84,85,111,133 and it
has not been feasible up to now in routine practice to
sequentially test for macroscopic and microscopic mucosal
healing in order to stratify the impact of chemoprevention
according to the inflammation status; finally, one observa-
tional cohort study suggested that 5-ASA is not able to
significantly decrease the progression from low-grade dys-
plasia to more advanced stages of neoplasias,138 and the
studies assessing specifically the relation between current
exposure to 5-ASA and the risk of dysplasia failed to
demonstrate, taking into account a more limited statistical
power, a signal toward a chemopreventive effect of 5-ASA on
dysplasia.82,84,123,131 This raises the hypothesis that 5-ASA
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periods impacts on early steps of inflammation-related
carcinogenesis.
9.4.3. Immunosuppressants
Immunomodulators (thiopurines and methotrexate) and
biologics (anti-TNF) could theoretically either increase the
risk of CRC via immunosuppression, or be chemopreventive
via a reduction of chronic mucosal inflammation. There are
no data for methotrexate and anti-TNF and the data for
thiopurines conflict.84,85,87,122,129,139,140 These included the
only published study specifically designed to address the
chemopreventive effect of thiopurines on the risk of CRC in
IBD.140 There is no evidence for a specific antineoplastic
action of thiopurines thus one must assume that thiopurines
would diminish the risk of colorectal cancer mainly via an
anti-inflammatory effect. If this is true, the effect of
thiopurines should be best demonstrated in the subgroup of
patients at most risk of inflammation-driven CRC, namely
patients with longstanding extensive colitis. The proportion
of IBD patients at high risk of CRC in stable clinical remission
on thiopurines who have no persistent mucosal microscopic
inflammation (i.e. the good candidates for the chemopre-
ventive effect of thiopurines) is low,141 and it is currently
impossible to perform subanalysis of such patients in clinical
epidemiological studies.
When analysing published series in detail, the use of
thiopurines80,84,85,87,122,129,139,140 appears restricted to the
most severe patients in a classical step-up approach, raising
the hypothesis that patients exposed to thiopurines had a
level of chronic colonic inflammation at least as severe as
patients not exposed. As an illustration, in the study by
Matula et al.,140 patients exposed to thiopurines were
more prone to receive corticosteroids or require surgery
suggesting a greater mean intrinsic “inflammatory severity.”
In the nested case–control study Olmsted population,87 less
than 10% of the case and control patients were exposed to
thiopurines. This rate was b1% in the study by Terdiman et
al.,129 suggesting again drugs were used only in the most
severe patients. A more relevant insight may come from
tertiary care or population–based cohorts with an early
and extensive use of thiopurines, which therefore include a
significant proportion of stable responders with no persis-
tent inflammation. In the prospective observational CESAME
cohort, one third of the patients were exposed to
thiopurines, and it was possible to show in a subgroup of
the cohort that the overall yearly clinical activity of IBD in
patients exposed to thiopurines was not higher than in
patients naïve to immunosuppression.142 In this cohort,
thiopurine use was associated with a three-fold reduction in
the risk of advanced neoplasias (high-grade dysplasia and
CRC) in IBD patients at high risk of inflammation-driven
cancers (longstanding extensive colitis), This trend must be
confirmed in other large cohorts with early and extensive
use of immunosuppressants.
9.4.4. Other drugs
Patients enrolled in a randomised controlled trial of
ursodeoxycholic acid in UC patients with PSC143 receiving
active drug experienced a significant reduction in CRC
suggesting that ursodeoxycholic acid should be given to
patients with UC and PSC.131–133 Folic acid supplements,calcium, multivitamins, or statins have not been consistently
associated with lower rates of CRC in UC, and no important
study in this field has been published since the first
evidence-based European consensus on the management of
UC.131
Statement 9M
Chemoprevention with 5-ASA compounds may
reduce the incidence of colorectal cancer in UC
patients and should be considered for all UC
patients [EL2, RG B]. Colorectal cancer chemo-
prevention with ursodeoxycholic acid should be
given to patients with PSC [EL1b, RG B]. There is
insufficient evidence to recommend for or against
chemoprevention with thiopurines9.5. Management of dysplasia
Therapeutic recommendations for management of dysplasia
in UC are based on macroscopic pattern (flat or elevated)
and microscopic characteristics of the lesion (indefinite, low
grade or high grade).111,144,145
9.5.1. Microscopic patterns of dysplasia
The current, widely used definition of dysplasia was
proposed by Riddell et al. in 1983.145 Dysplasia was defined
as unequivocal neoplasia of the epithelium confined to the
basement membrane, without invasion into the lamina
propria. Dysplasia is the best and most reliable marker of
an increased risk of malignancy in patients with IBD.146
Dysplasia (intraepithelial neoplasia—IEN) is now generally
classified according to the grade of neoplastic change into 3
morphologic categories: “indefinite,” “low grade” (LGD), or
“high grade” (HGD).145 However, dysplasia almost certainly
evolves along a progressive (continuous) scale rather than in
discrete categories. This contributes to the significant
degree of variability in interpretation of the grade of
dysplasia even among experienced gastrointestinal patholo-
gists.147,148 Levels of agreement are highest for the category
of HGD and for specimens considered negative for dysplasia,
and lower for specimens in the indefinite and LGD catego-
ries. These limitations in the assessment of dysplasia have
led to the recommendation that histological slides should be
reviewed by a second expert gastrointestinal pathologist.
9.5.2. Macroscopic patterns of dysplasia
Statement 9N
Endoscopically visible dysplastic raised lesions
within an area within the extent of ulcerative
colitis can be divided in adenoma-like and
non-adenoma-like by their macroscopic charac-
teristics [EL 2a, RG B]
12Statement 9O
Presence of low grade or high grade dysplasia
should be confirmed by an external second
pathologist [EL 1b, RG B]
There is inconsistency in the literature about the defini-
tions used to designate the macroscopic characteristics of
dysplastic lesions in UC.111,144 Some studies categorise
dysplastic lesions as flat only if they are endoscopically
undetectable, whereas others include visible plaque-like or
slightly raised areas of mucosa in this category also. For
the purpose of this evidence-based consensus, flat dysplasia
refers to endoscopically undetectable lesions, whereas raised
dysplasia refers to any type of endoscopically detectable
lesions.
Raised lesions with dysplasia (RLD) in UC have been broadly
separated into those that appear similar to non-IBD related
sporadic adenomas, referred to as “adenoma-like,” and those
which do not resemble adenomas: “non-adenoma-like” (the
former term “DALM”).149 Adenoma-like RLDs represent well
circumscribed, smooth or papillary, nonnecrotic, sessile, or
pedunculated polyps that are usually amenable to removal by
routine endoscopic methods.133,134 Non-adenoma-like lesions
include velvety patches, plaques, irregular bumps and nodules,
wart-like thickenings, stricturing lesions, and broad-based
masses,111,149–151 and are not usually amenable to removal by
colonoscopic polypectomy. Non-adenoma, and adenoma-like
RLDs are differentiated on the basis of their gross (endoscopic)
appearance. Histological features may be helpful,152 although
both types of lesions may appear identical.153,154
Polyps with dysplasia arising proximal to the macroscopic
and histologic involvement by the chronic inflammatory
process are considered sporadic and should be treated
accordingly.
9.5.3. Management of raised dysplasia
Statement 9P
Adenoma-like raised lesions can be adequately
treated by polypectomy provided the lesion can be
completely excised shows absence of dysplasia at
the margins of the specimen, and there is no
evidence of flat dysplasia elsewhere in the colon,
either adjacent to, or distant from, the raised lesion
[EL 2a, RG B]
Statement 9Q
Patients with non-adenoma-like raised lesions
should undergo a colectomy, regardless of the grade
of dysplasia detected on biopsy analysis because of
the high association with metachronous, or synchro-
nous, carcinoma [EL 2a, RG B]Statement 9R
Polyps with dysplasia that arise proximal to the
G. Van Assche et al.segments with macroscopic or histologic involve-
ment are considered as sporadic adenomas and
should be treated accordingly [EL 2c, RG B]Adenoma-like RLDs can be adequately treated with
polypectomy and continued surveillance. Four studies have
shown no significant difference in the incidence of polyp
detection on follow-up between patients with UC and an
adenoma-like RLD and patients with UC and a sporadic
adenoma, or between either of these two groups of UC
patients and a non-UC sporadic adenoma control
group.111,152,155,156 In one study, 70 dysplastic polyps were
resected from 48 patients; during a mean follow-up period of
4.1 years, colonoscopies revealed additional polyps in
48% but none developed carcinoma.156 Another study
included 34 UC patients, 24 with adenoma-like RLDs and 10
with sporadic adenomas, 28 of which were treated by
polypectomy; 58.8% of patients with adenoma-like RLDs
developed at least one further adenoma-like RLD on
follow-up evaluation, one patient had flat low-grade
dysplasia, which was resected within 6 months of the initial
polypectomy, and another patient, with primary sclerosing
cholangitis, developed adenocarcinoma 7.5 years after
initial polypectomy. There was no significant difference in
the prevalence of polyp formation on follow-up evaluation
between UC patients with an adenoma-like RLD (62.5%) and
UC patients with a sporadic adenoma (50%), or between
either of these two UC patient subgroups and a non-UC
sporadic adenoma control group (49%).155 Another study
of 40 patients undergoing endoscopic resection of
adenoma-like RLDs reported one case of adenocarcinoma
after a mean follow-up period of 4.2 years111 this was not
significantly different from the frequency of cancer within
the surveillance population as a whole. Finally, in one recent
follow-up study including 148 patients with UC adenoma-like
lesions, 87 patients were treated with polypectomy; during a
mean follow-up period of 6 years only 4.6% developed
dysplasia (2 of which were ultimately diagnosed with
carcinoma).152
Biopsies should be taken from the flat mucosa surrounding
any dysplastic polyp to assess whether it is involved in the
chronic inflammatory process and also to assess whether there
is any dysplasia in the surrounding flat mucosa. If an
adenoma-like RLD111,152,155–157 is detected within an area of
inflammation it can be treated conservatively by polypectomy
provided the lesion can be completely excised, shows absence
of dysplasia at the margins of the specimen, and there is no
evidence of flat dysplasia elsewhere in the colon, either
adjacent to, or distant from, the RLD.
There is a strong association of metachronous or
synchronous carcinoma with non-adenoma-like RLDs, rang-
ing from 38% to 83%.144 For this reason, it is generally
recommended that patients with UC and an endoscopically
unresectable non–adenoma-like RLD should undergo a
colectomy, regardless of the grade of dysplasia detected
on biopsy analysis. However endoscopic mucosal resection
has been used for treatment of non-adenoma-like lesions in
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approach, there was a larger recurrence rate compared to
endoscopic mucosal resection for sporadic lesions (14% vs. 0%,
respectively) after a median follow-up of 4.8 years.158 Finally,
if a dysplastic polyp occurs in an area proximal to the
microscopic level of inflammation, with no dysplasia in flat
mucosa, it can be regarded as a sporadic adenoma and treated
accordingly.156,159
9.5.4. Management of flat dysplasia
Statement 9S
Flat high-grade dysplasia warrants a recommen-
dation of colectomy because of the risk of a
concomitant or future colorectal cancer [EL 2a,
RG B]
Statement 9T
The current evidence is insufficient to assess the
balance of risks and benefits of colectomy for flat
low-grade dysplasia. The decision to recommend
colectomy or continued surveillance is best
tailored to the individual after careful discussion
[EL 5, RG D]
Current evidence indicates that at the time flat HGD
dysplasia is discovered, CRC may already be present in 42% to
67% of cases, although this estimation is based on three
studies that include a limited number of cases with HGD
(from 6 to 24 patients).102,160,161 Furthermore, a review of 10
prospective surveillance trials found that 15 of 47 patients
(32%) with HGD developed CRC upon further follow-up,160
and updated data from the St Mark's surveillance programme
indicated that 2 of 8 patients (25%) with HGD who did not
have immediate colectomy, progressed to CRC.78 Overall,
the immediate and subsequent risk of CRC in patients with
flat HDG is large enough to warrant a recommendation for
colectomy.
Recommendations on the optimal management of UC
patients with flat LGD are more controversial, in part
because not every study reporting the outcome of LGD
distinguished between raised and flat lesions. Although the
rate of synchronous CRC is lower for LGD than HDG, it is still
considerable. Results of three studies including 10, 11 and
16 patients with LGD identified CRC in colectomy specimens
in 20%, 27% and 19%, respectively.78,160,162 A meta-analysis
of 20 surveillance studies analysed the cancer risk of 477
patients with flat LGD and 31 patients with LGD in a RLD.163
The incidence of CRC was 14 per 1000 patient-years. For
HGD and/or CRC, it was 30 per 1000 patient-years. The
positive predictive value of flat LGD was 22% for synchro-
nous CRC and 36% for synchronous HGD and CRC. The
positive predictive value for progression to HGD and CRC
was 14.6%. If LGD was detected in a RLD, the rates ofsynchronous and metachronous cancer were higher. Over-
all, when LGD is detected on surveillance, there is a 9-fold
increased risk of developing CRC, and a 12-fold risk of
developing HGD or CRC.163
Estimates for the risk of progression from LGD to HGD
and CRC, if the lesions are left in place, vary among
published studies. The aforementioned meta-analysis indi-
cated that the positive predictive value is approximately
14.6% for progression of flat LDG to HGD and/or CRC, with
significant variability present between studies.163 High
rates of progression have generally been reported in
retrospective studies, ranging from 23% on an updated
30-year follow-up from the St Mark's hospital to 33% and
53% 5-year progression in series from the Mayo Clinic164 and
Mt Sinai New York162 hospitals, respectively. In contrast,
other prospective studies have reported lower rates of
progression in patients with LGD. One study found only a 3%
initial, and 10% subsequent, rate of progression to CRC
during a 10-year follow-up period. Since these rates were
not significantly higher than the 0.8% and 3% progression
rates among patients without dysplasia, this observations
suggests that LGD may not be associated with a higher risk
of CRC.101 Likewise, a prospective Swedish study found no
progression to CRC, and only 2 cases of progression to
HGD, over a 10-year period.165 Furthermore, a summary of
8 studies revealed that after a diagnosis of LGD was made,
subsequent surveillance, with an average of 4.3 colonos-
copies per patient, detected more HGD lesions (n=47)
than CRCs (n=18) or RLDs (n=8).163 This may be important
if one considers the goal of surveillance to be the
prevention of mortality from CRC rather than the detection
of HGD.
There may be a difference in natural history of LGD
depending on whether dysplasia is found on the initial
screening colonoscopy (prevalent dysplasia) or during sur-
veillance colonoscopy (incident dysplasia). A review of 10
prospective studies reported that HGD or CRC developed in
15/55 patients with prevalent dysplasia (29%) in comparison
with 33/204 (16%) of those with incident dysplasia.160 As for
the relevance of focality of dysplasia, it has been sometimes
assumed that unifocal lesions would be at lower risk of
progression that multifocal dysplasia. However, a recent
study found that the overall 5-year progression rate of flat
LGD to either HGD or CRC was similar in unifocal and
multifocal dysplasia.164
The current evidence is insufficient to assess the balance
of risks and benefits of colectomy for flat LGD. Thus, the
decision to undergo colectomy versus continued surveillance
in patients with flat LGD should be individualised and
discussed at length between the patient, the gastroenterol-
ogist and the colorectal surgeon. Colectomy will eradicate
the risk of CRC, but if a patient is unwilling to undergo
colectomy, yearly surveillance is recommended.13310. Psychosomatics
10.1. Introduction
The controversies about the role of psychosocial factors
in UC have been addressed in systematic reviews.166–169
A biopsychosocial model170,171 represents an advantage over
14 G. Van Assche et al.a biomedical model, because it embodies the complex
biological and psychosocial interactions that explain human
illness. Attention to psychosocial factors associated with
ulcerative colitis may have consequences not only on
psychosocial well-being and quality of life, but also on the
activity of the disease itself.10.2. Influence of psychological factors on disease
10.2.1. Etiology
Statement 10A
There is no conclusive evidence for anxiety,
depression and psychosocial stress contributing
to risk for UC onset [EL2c, RG D]
A retrospective nested case–control study with 12,500
participants examined temporal relationships without po-
tential recall bias, limited to patients with UC who obtained
treatment for depression or anxiety before UC diagnosis. A
significant association was found between depression and UC
(OR 1.49, 95% CI 1.12–1.93) when the depression predated
UC by more than 5 years, which is unlikely to be influenced
by initial UC symptom presentation.172 Prospective studies
on psychosocial stress as a risk for UC onset have not been
conducted until now.10.2.2. Course of disease
Statement 10B
Psychological factors may have an impact on the
course of UC. Perceived psychological stress [EL2a,
RG B] and depression [EL2a, RG B] are risk factors
for relapse of the disease. Depression is associated
with low health-related quality of life [EL3a, RG B].
Anxiety is associated with non adherence with
treatment [EL4, RG C]
A systematic review demonstrated an association
between psychological stress and disease activity in
patients with UC.167 Another systematic review reported a
significant relationship between stress and inflammation
in 4 longitudinal studies assessing the impact of stress
or depression on disease course.169 A prospective study
demonstrated that only high perceived stress (adjusted
OR=2.40, 95% CI, 1.35–4.26) was significantly associated
with symptomatic flares.173 Higher anxiety and depression
at baseline were related to more frequent relapses in the
follow-up period in a second prospective study.174 Another
study did not find an increased risk of relapse in patients
diagnosed with depressive disorder by a psychiatric inter-
view.175 Depression176,177 and neuroticism178 were associ-
ated with low health-related quality of life. Anxiety andmoodiness were associated with nonadherence with
UC-treatment.179
10.3. Psychological disturbances in ulcerative colitis
Statement 10C
Psychological distress and mental disorder are
more common in patients with active ulcerative
colitis than in population-based controls, but not
in patients in remission [EL3a, RG B]
Statement 10D
Clinicians should particularly assess depression
among their patients with active disease and those
with abdominal pain in remission [EL 2b, RG B]
A systematic review demonstrated that anxiety and
depression are associated with disease activity. However,
the prevalence of mental disorders (anxiety and depres-
sive disorders) in patients with active disease is comparable
with the one of patients with other chronic somatic
diseases.176 Patients in remission do not differ in the
amount of psychological distress and the frequency of
mental disorders (anxiety and depressive disorders) from
general population controls.180 There are contradictory
findings on the association between gender and depression
in patients with active UC.180–182 A consistent association
between anxiety and depressed mood and the prevalence
of IBS-like symptoms in patients in remission has been
reported.183–185
10.4. Approach to psychological disorders
10.4.1. Communication with patients
Statement 10E
The psychosocial consequences and health-
related quality of life of patients should be taken
into account in clinical practice at regular visits.
Individual information and explanation about
the disease should be provided through a
personal interview [EL3b, RG B]. Patients' disease
control can be improved by combining self-
management and patient-centred consultations
[EL1b, RG B]
Health perceptions impact on the experience of the
illness.186 Increasing physician awareness of the fact that
psychologically distressed patients have difficulty in pro-
cessing clinically relevant information187 may lead to
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that patients are informed about their condition through an
individual interview, in conjunction with emotional support.
This is because a lower level of information is associated
with greater concern.189 Since approximately half of the
patients in IBD referral centres use the internet to gather
IBD-related information,190,191 web-based communication
programmes seem be feasible and to increase the level of
disease specific knowledge.192 Psychosocial factors are
strongly correlated with health care utilization.193 Medical
non-adherence has been reported in over 40% of patients,
and this is a situation in which the patient-doctor relation-
ship also plays a key role.194 Self-management guidebooks
together with patient-centred consultations improve pa-
tients' disease control.195,196 It should however be
recognised that educational booklets on their own do not
seem to be helpful and may even worsen the health-related
quality of life of patients attending tertiary centres.197 In
addition, patient education programmes seem to have very
limited or even no influence on the course of their illness,
their health-related quality of life, or their psychological
effect.198–202
10.4.2. Psychological support
Statement 10F
Physicians should screen patients for anxiety,
depression and need for additional psychological
care and recommend psychotherapy if indicated
[EL 2b, RG B]. Patients should be informed of
the existence of patient associations [EL 5, RG D]
The presence of psychological disorders contributes to
poor quality of life and the number of doctor visits,
regardless of the severity of the condition.193 A validated
questionnaire based on inflammatory bowel disease is
available to assess the demand for psychological
care.203,204 Approximately one third of patients attending
an IBD centre express a need for psychological interven-
tion.204 Anxiety, younger age as well as impaired social
support increased this demand. Detection and treatment of
psychological distress has the potential to improve
health-related quality of life.205 For assessment of quality
of life, two validated IBD-specific questionnaires have been
shown to be sensitive, reproducible and responsive for use in
clinical trials: the Inflammatory Bowel Disease Question-
naire (IBDQ)206 and the Rating Form of Inflammatory Bowel
Disease Patient Concerns (RFIPC).207 Since strategies aimed
at improving social support can have a favourable impact on
psychological distress,208,209 training gastroenterologists to
integrate psychosocial factors in clinical practice is impor-
tant. Because patients describe deficiencies in the care of
family members, insufficient information and inadequate
access to healthcare resources,210 integrated psychosomatic
care should be available. Integrated psychosomatic care can
be defined as a combined somatic (gastroenterology) and
psychological (psychotherapist, psychologist, psychiatrist)
care of patients, especially in tertiary centres.10.4.3. Therapeutic intervention
Statement 10G
Psychotherapeutic interventions are indicated for
psychological disorders and low quality of life
associated with ulcerative colitis [EL 1b, RG B]
Some studies have shown that psychotherapy and relax-
ation methods have a positive influence on the psychological
dimensions of the illness such as psychological well-being,
coping strategies, quality of life and psychological
distress211–216 as well as perception of pain.217 The effects
of psychosocial interventions on quality of life, coping,
emotional state and disease activity in ulcerative colitis
were assessed in a systematic review.218 The authors
concluded that psychotherapeutic interventions in general,
if applied to unselected patients, are not likely to have a
relevant positive effect. Therefore, the diagnosis of ulcer-
ative colitis is insufficient alone to recommend psychother-
apy in adult patients, but in adolescents, psychological
interventions may be beneficial.218
10.4.4. Therapeutic choice
Statement 10H
The choice of psychotherapeutic method depends
on the psychological disturbance and should best
be made by specialists (Psychotherapist, Special-
ist for Psychosomatic Medicine, Psychiatrist).
Psychopharmaceuticals should be prescribed for
defined indications [EL 5, RG D]
There is no evidence that one psychotherapeutic method
should be preferred over another. Relaxation exercises are
useful,216,217 since they are easy to learn and perform.
Expert opinion believes that there is an advantage if the
psychotherapist has experience in the treatment of patients
with chronic inflammatory bowel diseases and works closely
with the patient's gastroenterologist. There are no specific
studies on the use of individual psychopharmaceuticals in
ulcerative colitis.219 In spite of this, almost all experts
believe that there are clinical situations in which antide-
pressants should be recommended for treatment of psycho-
logical distress associated with ulcerative colitis.11. Extraintestinal manifestations of
ulcerative colitis
11.1. Introduction
Extraintestinal manifestations (EIMs) are common in UC
affecting up to 35% of patients.220,221 Detailed prospective
studies using adequate diagnostic criteria are rare. Most
16 G. Van Assche et al.reports are retrospective and based on review of patients'
files. The occurrence of one EIM often seems to predispose
to others. The activity of certain EIMs such as peripheral
arthritis, erythema nodosum, oral aphthous ulcers and
episcleritis are related to UC activity. In contrast, pyoderma
gangrenosum, uveitis, axial arthropathy and primary scle-
rosing cholangitis (PSC) usually run an independent course.
For those EIMs whose activity mirror the colitis, treatment
can parallel that of the underlying disease. Treatment
otherwise is mainly on a case by case basis as RCTs are
lacking. This section concentrates on the more frequently
encountered EIMs for which at least some quantifiable data
exist, and does not include systemic consequences of severe
UC such as iron deficiency or malnutrition.
Statement 11A
Diagnosis of non-axial arthritis and arthropathy
associated with UC is made on clinical grounds
based on characteristic features and exclusion of
other specific forms of arthritis [EL3b, RG C]. Type I
is pauciarticular and affects large joints acutely
at times of UC activity Type II is polyarticular,
affecting a larger number of peripheral joints
independently of UC activity [EL2b, RG B]. Axial
arthritis, including sacro-iliitis and ankylosing spon-
dylitis, is diagnosed on conventional rheumatolog-
ical grounds, and is supported by characteristic
radiological changes, magnetic resonance imaging
being themost sensitive [EL2b, RG B]. Although HLA
B27 is over-represented in axial arthritis related to
UC this is not of diagnostic value [EL2b, RG B]
11.2. Arthropathy
11.2.1. Peripheral arthropathy
The Oxford group subclassified peripheral arthropathy into
type I and type II, but only type I is associated with intestinal
disease activity.222 Type 1 is pauciarticular and affects large
(predominantly weight bearing) joints including the ankles,
knees, hips, wrists and sometimes elbows and shoulders. By
convention less than five joints are affected. The arthritis is
acute, self limiting (weeks rather than months) and typically
asymmetric. This arthropathy is observed in 4–17% of patients
with UC. Type II is a polyarticular arthritis mainly affecting the
small joints of the hand but independent of UC activity and is
observed is 2.5% of patients with UC.222 The diagnosis of
arthritis is made clinically from the finding of painful swollen
joints (synovitis). The differential diagnosis includes osteoar-
thritis, rheumatoid arthritis and arthritis associated with
connective tissue diseases such as lupus. It has to be
differentiated from arthralgia (which may complicate corti-
costeroid withdrawal), osteonecrosis related to corticoste-
roids, and infliximab related lupus-like syndrome.223
11.2.2. Axial arthropathy
Axial arthropathy includes sacroiliitis and spondylitis.
Irrespective of the presence of inflammatory back pain,isolated radiographic sacroiliitis has been found in 25–50%
of patients with UC.224–226 The diagnosis of ankylosing
spondylitis (AS) according to the modified Rome criteria227
includes a chronic inflammatory back pain (at night and at
rest, improving by exercise), morning stiffness, limited
spinal flexion and, in later stages, reduced chest expansion.
Radiographs demonstrate sacroiliitis, syndesmophytes and
bone proliferation evolving to ankylosis (“bamboo spine”).
While computed tomography is more sensitive for detecting
structural abnormalities than simple radiographs, the
current gold standard is magnetic resonance imaging due
to its ability to demonstrate inflammation before bone
lesions occur.228,229 The overall prevalence of AS in IBD
ranges from 4–10%. HLA-B27 is found in 25–75% of patients
with UC and ankylosing spondylitis224,230–232 but only
in 7–15% of patients with isolated sacroiliitis. HLA-B27
positive IBD patients seem to be at risk for the development
of AS.23211.2.3. Treatment of arthropathy related to
ulcerative colitis
Statement 11B
In peripheral arthritis treatment of the underlying
UC is normally effective in relieving symptoms [EL
5, RGD]. For persistent symptoms in the absence
of active UC there is general support for use of
short term treatment with non-steroidal anti-
inflammatory agents. Local steroid injections and
physiotherapy are also effective [EL4, RG D].
Sulfasalazine has a role in persistent peripheral
arthritis [EL1a, RG B]. In axial arthropathy argu-
ments in favour of intensive physiotherapy [EL2a,
RG B], associated with NSAIDs are stronger, but
safety concerns mean that long-term treatment
with NSAIDs is best avoided if possible [EL1b, RG B].
Sulfasalazine [EL1a, RG B], methotrexate [EL1b,
RG B] and azathioprine [EL3b, RG C] are generally
ineffective, or only marginally effective. The effi-
cacy of anti-TNF therapy for patients with ankylos-
ing spondylitis and UC intolerant or refractory to
NSAIDs is well established [EL1b, RG B]
Recommendations for the treatment of IBD-related
arthropathy are based on studies in spondyloarthropathy,
predominantly ankylosing spondylitis. No single prospec-
tive controlled trial in IBD patients is available in the
literature. Only small open-label trials or case reports are
published.233–236
In peripheral arthritis the emphasis should be on the
treatment of the underlying UC, including corticosteroids,
immunomodulators and anti-TNF agents as appropriate.
Symptomatic relief may be obtained by rest and physio-
therapy. Although there is concern that NSAIDs may
aggravate the underlying UC237,238, this risk seems
low, particularly if prescribed at low dose and for short
17Second European evidence-based consensus on ulcerative colitis' diagnosis and managementduration.239 The use of COX-2 inhibitors such as etoricoxib
and celocoxib appears safer with a lower risk of disease
flare than conventional NSAIDs.240,241 A beneficial effect
of sulfasalazine on large joint arthropathy has been
reported.242,243 Several open-label studies and some
controlled trials have demonstrated an impressive effect of
IFX on peripheral arthritis.244
Treatment of axial arthropathy in UC is based on
evidence from ankylosing spondylitis. It should include
intensive physiotherapy. NSAIDs are the mainstay of
medical therapy and recommended as first line therapy in
AS. However long-term treatment with high-dose NSAIDs is
generally inadvisable in patients with UC. The effect of
corticosteroids is poorly reported. Local corticosteroid
injections can be considered. Sulfasalazine, methotrexate
and azathioprine are considered to be ineffective or only
marginally effective in AS with axial symptoms.245 In
patients with active AS refractory to or intolerant of
NSAIDs, anti-TNF agents are recommended. The efficacy
and safety of IFX and ADA in ankylosing spondylitis are now
well established.228,244,246–25111.3. Metabolic bone disease
Low bone mass and osteoporosis are common in both male
and female patients with UC (20%–50%). Contributing factors
include chronic inflammation, corticosteroid treatment,
age, smoking, low physical activity and nutritional deficien-
cies.252 Diagnosis of osteoporosis is best made by a T
scoreb−2.5 on bone densitometry (DEXA scanning) in
patients over 50 years old and in patients under 50 “low
bone mass” is defined by a Z-score b2.0.
Statement 11C
Diagnosis of osteoporosis in adults is best made
from a T score of less than −2.5 on radiographic
bone densitometry [EL1a, RG A], all other diag-
nostic methods having current limitations [EL2b,
RG B]. The presence of osteoporosis identifies
patients at above average risk for fracture and
who should receive treatment [EL2b, RG B]
The precision and reproducibility of ultrasound and
Q-CT is not sufficient for repeated clinical measure-
ments.253 DEXA scanning is best performed in all patients
with persistently active UC, in those repeatedly exposed to
corticosteroids and patients with long disease duration.
The presence of osteoporosis identifies patients at above
average risk for fracture, who should receive treatment.
The presence of osteoporosis is one (but not the only) risk
factor for fractures of the spine and peripheral long bones.
In recent studies, vertebral fractures have been document-
ed in patients with both reduced and normal bone density;
challenging the concept that osteoporosis is the main
risk factor for vertebral fractures in young patients with
IBD.254–256 The strongest predictor of future fracture is
a prior vertebral fracture. There is, therefore, a needfor prospective studies in young and premenopausal IBD
patients to establish a valid assessment tool like the FRAX
index used for postmenopausal women.257,258
Statement 11D
Osteopenia may be a prognostic marker for future
osteoporosis, but presents little direct risk [EL2b,
RG C]. However if the T score is less than −1.5,
treatment with calcium and vitamin D should be
recommended [EL4, RG C]. Pre-existing history of
fracture is of substantial adverse prognostic signif-
icance and patients should be treated for osteopo-
rosis even if the T score is normal [EL4, RG C]
Treatment with calcium 500–100 mg/day and vitamin D
(800–1000 IU/day) increases bone density in patients
with IBD.252 The value of calcium and vitamin D in
preventing fractures has not been demonstrated in patients
with IBD, although there is value in postmenopausal or
steroid-induced osteoporosis.259 Various bisphosphonates
increase bone density in patients with UC (for review
see INS; Ref. 252). Fracture prevention with bisphosphonates
has been clearly established in postmenopausal women
and steroid-induced osteoporosis but not in young,
premenopausal patients with UC. Therefore a general
recommendation of treatment with bisphosphanates on the
basis of reduced bone density is not feasible. In individual
patients with low bone density and additional risk factors
treatment should be considered.
Statement 11E
Weight-bearing exercise [EL2b, RG B], stopping
smoking [EL3b, RG C], avoiding alcohol excess
[EL4, RG D], and maintaining adequate dietary
calcium (N1 g/day) [EL 2b, RG B] are beneficial.
In post-menopausal women with osteoporosis,
regular use of bisphosphonates, calcitonin and
its derivatives, and raloxifene reduce or prevent
further bone loss [EL2b, RG C]. Data in males with
osteoporosis are less secure but bisphosphonates
are probably of value [EL3 b, RG C]. Newer data
also support the use of strontium salts [EL2a,
RG B]. Patients receiving systemic steroid therapy
should receive calcium and vitamin D for prophy-
laxis [EL5, RG D]
Patient's with persistently active disease should be treated
according to guidelines with immunosuppressive therapy
(azathioprine, TNFα antibodies) to avoid prolonged steroid
treatment and general inflammatory activity. It has been
shown that a significant proportion of patients with IBD
are able to normalise their bone density after 3 years in stable
remission.260 Newer drugs like teriparatide, strontium
18 G. Van Assche et al.ranelate or recombinant OPG should be prospectively studied
in patients with UC before their use can be recommended.
11.4. Cutaneous manifestations
Statement 11F
Diagnosis of the cutaneous manifestations of IBD
is made on clinical grounds, based on their
characteristic features and (to some extent) the
exclusion of other specific skin disorders; biopsy
can be helpful in atypical cases [EL3b, RG C]
Statement 11G
Treatment of erythema nodosum is usually based
on that of the underlying Ulcerative Colitis.
Systemic steroids are usually required [EL4, RG
D]. Pyoderma gangrenosum is initially treated
with systemic steroids, topical or oral calcineurin
inhibitors [EL4, RG D], infliximab [EL1b, RG C] or
adalimumab [EL3b, RG C]Statement 11H
Anti-TNF treatment can induce paradoxical in-
flammation of the skin [EL4] which is a class-drug
effect and is usually reversible upon drug cessa-
tion [EL4]. When diagnosis is uncertain, referral
to a dermatologist for expert opinion is
recommended [EL5 RG D]. Treatment is based11.4.1. Erythema nodosum (EN)
EN is readily recognised and characterised by raised,
tender, red or violet subcutaneous nodules of 1–5 cm in
diameter. It commonly affects the extensor surfaces of the
extremities, particularly the anterior tibial areas and usually
occurs at times of UC activity. A firm clinical diagnosis can
normally be made and biopsy is not usually appropriate. If
performed, the histology reveals a non-specific focal
panniculits.261,262 The prevalence of EN in IBD ranges from
4.2–7.5%221,263,264 and seems to be higher in CD than in
UC.264 The differential diagnosis includes metastatic CD,
which may appear at any site as solitary or multiple nodules,
plaques, ulcers, or violaceous perifollicular papules, the
histology of which includes non-caseating granulomas.265
Because EN is closely related to disease activity despite a
genetic link,266 treatment is based on that of the underlying
UC. Systemic steroids are usually required. In resistant cases
or when there are frequent relapses, immunomodulation
with azathioprine, infliximab or adalimumab may be
used.267,268
11.4.2. Pyoderma gangrenosum (PG)
Lesions are often preceded by trauma at the site through
a phenomenon known as pathergy.269 PG can occur any-
where on the body, including the genitalia, but the
commonest sites are on the shins and adjacent to stomas.
Initially they take the form of single or multiple erythema-
tous papules or pustules, but subsequent necrosis of the
dermis leads to the development of deep excavating
ulcerations that contain purulent material that is sterile on
culture unless secondary wound infection has occurred. In
recent publications 0.6–2.1% of UC patients developedPG.263,264,270 PG may parallel the activity of the underlying
UC or run a course that is independent of it. PG is a diagnosis
of exclusion and might be misdiagnosed in a substantial
percentage of cases.271 Histopathological findings in PG are
non-specific, but biopsy can be helpful to exclude other
specific skin disorders.
Rapid healing should be the therapeutic goal, because PG
can be a debilitating skin disorder. There is no evidence that
the efficacy of treatment strategies for PG differs between
IBD and non-IBD patients. Immunosuppression is the main-
stay of treatment. Traditionally the most commonly used
drugs with the best clinical experience were systemic
corticosteroids and ciclosporin. Corticosteroids have been
considered first line treatment, with intravenous ciclosporin
and oral and intravenous tacrolimus reserved for refractory
cases.272–275 Infliximab has, however, changed the manage-
ment of PG in patients with UC. Its effectiveness was first
reported in small case studies.276 The largest study on the
treatment of PG with IFX was a multicentre, randomised,
placebo-controlled trial of 30 patients, including 19 patients
with IBD.277 IFX 5 mg/kg or placebo was given at week 0. At
week 2 (the primary end point), significantly more patients
in the IFX group had improved compared to placebo (46% vs.
6%, p=0.025). At week 2, subjects in both arms were then
offered open-label IFX. Overall, 29 patients received IFX
with the majority of them demonstrating a beneficial
clinical response: response 69%, remission 31% at week 6.
The response rate was over 90% in patients with short
duration of PG (b12 weeks) and less than 50% in those with
disease present for more than 3 months. Until now, no trial
has compared the efficacy of different immunosuppressive
drugs. IFX should be considered if a rapid response to
corticosteroids cannot be achieved. In patients with
peristomal PG, closure of the stoma might lead to resolution
of the PG lesions.278 Topical tacrolimus is an alternative, but
specialist advice is recommended.
11.4.3. Sweet's syndrome
Sweet's syndrome is characterised by tender, red inflam-
matory nodules or papules, usually affecting the upper limbs,
face or neck.279 It has only been recognised as an
extraintestinal manifestation of IBD relatively recently.280,281
It is part of the group of acute neutrophilic dermatoses that
includes pyoderma gangrenosum, but can be distinguished by
its appearance, distribution and histological features. There is
a strong predilection for women and patients with colonic
involvement and other extraintestinal manifestations. The
rash is mostly associated with active disease. Systemic
corticosteroids have been reported to be effective.
11.4.4. Anti-TNF-induced skin inflammation
almost entirely on extrapolation from paradoxical
skin inflammation in other chronic diseases and it
may include topical steroid therapy, topical
keratolytic agents, vitamin D analogues, metho-
trexate, switching anti-TNF or anti-TNF discon-
tinuation [EL3b RGC]
19Second European evidence-based consensus on ulcerative colitis' diagnosis and managementSeveral centres have reported the development of psoriatic and
eczematous lesions in patients with CD and UC receiving
anti-TNF therapy, an observation which did not seem to relate
to the age of the patient or the duration of treatment.282
Several isolated case reports have been described, and
controlled case-series have been published.282,283
Skin lesions are reported in approximately 22% of patients
treated on anti-TNF therapy. Psoriasiform eczema, eczema
and xerosis were the most commonly observed type of skin
lesions and anti-neutrophilic antibodies (ANA) were posi-
tively associated with skin paradoxical inflammation.284
In a French collaborative study, Rahier et al. assessed clinical
characteristics, risk factors, and outcomes of skin disease in
patients with inflammatory bowel diseases that presented with
psoriatic and eczematous lesions induced by anti-TNF-α
agents.283 A total of 85 patients including CD and UC that
developed psoriatic (62 patients) and eczematous lesions (23
lesions) were studied. Locations of eczematous lesions varied
whereas scalp and flexural varieties were mostly psoriatic. Skin
lesions were not associated with IBD activity, but were more
frequent among females and occurred with any type of
anti-TNF-α agent (infliximab, adalimumab or certolizumab).
Topical therapy with corticosteroids, keratolytics (salicylic
acid, urea), emollients, vitamin D analogues and ultraviolet
(UV) therapy (UVA or narrow band UVB) resulted in partial or
total remission in almost 50% of patients. Patients with psoriatic
lesions that did not improve with topical therapy and that
switched anti-TNF-α therapies occasionally developed recur-
rent lesions, suggesting class effect. Overall, 34% of patients
had to discontinue anti TNF agents due to uncontrolled skin
lesions.283 The largest case series, however, is derived from the
rheumatological literature, and the treatment is mainly based
on expert opinion.285,28611.5. Ocular manifestations
Statement 11I
Patients with ocular manifestations should be
referred to an ophthalmologist [EL5, RG D].
Episcleritis may not require systemic treatment
and will usually respond to topical steroids or
NSAID [EL4, RG D]. Uveitis is treated with
steroids, and it may be necessary to use both
topical and systemic routes [EL3b, RG C]. Immu-
nomodulatory therapy including anti TNF may be
helpful in resistant cases [EL4, RG D]
Uveitis and episcleritis are the most common ocular
manifestations of IBD. Episcleritis may be painless, presentingsimply with hyperaemic sclera and conjunctiva, but itching
and a burning sensation may also occur.287 Episcleritis may be
self-limiting but will usually respond to topical steroids or
NSAID, simple analgesics alongside the treatment of the
underlying UC.287
Uveitis is less common but has potentially more severe
consequences. When related to UC it is frequently bilateral,
insidious in onset and long-lasting.287 Patients complain of
eye pain, blurred vision, photophobia and headaches. The
possibility of progression to loss of vision should prompt
urgent referral to an ophthalmologist. Slit-lamp examination
will confirm the diagnosis and permit the differentiation
between anterior and posterior uveitis. The treatment will
usually consist of both topical and systemic steroids.287
Azathioprine, methotrexate, infliximab and adalimumab
have each been reported to be valuable in resistant cases.11.6. Hepatobiliary disease
Statement 11J
Diagnosis of hepatobiliary disorders in association
with ulcerative colitis follows the standard inves-
tigatory pathways prompted by abnormal liver
function tests, with ultrasound scanning, and
serology to identify specific auto-immune and
infective causes [EL2a, RG B]. Magnetic resonance
cholangiography is now established as the
first-line diagnostic test for primary sclerosing
cholangitis [EL2a, RG B]. Primary sclerosing
cholangitis substantially increases the risk of both
cholangiocarcinoma and colorectal carcinoma
[EL1a, RG A]
Liver test abnormalities are common in IBD and are
associatedwith a small but significant reduction in survival.288
Primary sclerosing cholangitis (PSC) constitutes the most
important condition relatively specific to the underlying IBD.
However, pericholangitis, steatosis, chronic hepatitis, cirrho-
sis, and gallstone formation are also over-represented. In
addition, many of the drugs used for IBD have the potential to
cause hepatotoxicity. In most cases, the condition will be
detected by abnormal liver function tests on routine screening
rather than symptoms or signs of liver disease. A predomi-
nantly obstructive pattern of liver enzymes or the presence of
biliary symptoms will prompt ultrasonographic assessment,
which may reveal gall stone disease, steatosis or frank
cirrhosis; less often it will show an abnormal duct pattern
suggestive of PSC. If ultrasound scanning is normal, drug side
effects have been thought unlikely, and serological tests for
other primary liver disease are negative then the probability
of PSC is significantly increased. The usual diagnostic test is
magnetic resonance cholangiography (MRCP), which will show
the characteristic pattern of irregular bile ducts, containing
areas of both narrowing and dilatation.289,290 If MRCP is
normal it is safer and probably more often diagnostic (given
probable predominant small duct disease) to perform a liver
biopsy than diagnostic endoscopic retrograde cholangiography
20 G. Van Assche et al.(ERCP) to confirm PSC.290,291 PSC is a major risk factor for
cholangiocarcinoma and colon cancer.291
Statement 11K
Ursodeoxycholic acid improves abnormal liver
function tests [EL1b, RG B], but not histology
and prognosis in PSC. ERCP should be used to treat
dominant strictures by dilatation and/or stenting
[EL4, RG C]. Advanced liver disease may necessi-
tate transplantation [EL2a, RG B]
Ursodeoxycholic acid (ursodiol) was promptly adopted as
a treatment for PSC once it was shown to improve liver
enzymes,292 but it has taken some time for reasonably
convincing evidence to emerge supporting true benefit from
a 20 mg/kg daily dose in respect of histological progression.293
However in a recent placebo-controlled study with high dose
ursodiol (28–30 mg/kg/day) patients in the ursodiol group had
a significantly worse outcome despite improvement of liver
function tests.294 Therefore, ursodiol doses should not exceed
20 mg/kg/day. Ursodiol may reduce the risk of colonic cancer
in patients with PSC.143,295 The benefit of steroid therapy has
been examined with conflicting results. Tacrolimus resulted
in a rapid decrease in liver enzymes but no histological
improvement296 ERCP may still be needed to confirm the
diagnosis of PSC in a few cases, and it remains the procedure of
choice to manage dominant biliary strictures.291 In advanced
disease with liver failure there is no alternative to liver
transplantation but recurrence of PSC in the transplanted liver
occurs in approximately 20% of patients.297 Because of the
higher risk of colorectal cancer, it is generally considered
appropriate to perform annual screening colonoscopy from
the time of diagnosis.11.7. Venous thromboembolism
Statement 11L
The risk of thrombosis and related mortality is
doubled in patients with UC compared to
controls [EL2, RG C]. In patients at risk for
thromboembolism prevention with both mechan-
ical thromboprophylaxis and heparin (LMWH or
UFH) should be considered [EL5, RG D]. Treat-
ment of venous thromboembolism in IBD should
follow established antithrombotic therapy options
[EL 1a, RG A] taking into account the potentially
increased risk of bleeding [EL5, RG D]
Patients with IBD are at increased risk for venous thrombo-
embolism (VTE), which represents an important cause of
morbidity and mortality. The prevalence of VTE in IBD
ranges between 1.2 and 6.7% in clinical studies.298–301 A
population-based study and a case–control study revealedthat IBD patients have at least a 2-fold greater risk than the
general population and control subjects, respectively.299,302,303
Furthermore, the risk of recurrence is increased in IBD patients
in comparison with non-IBD patients304 Deep venous thrombo-
ses (DVT) of the leg and pulmonary emboli (PE) are the most
common thromboembolic manifestations, but unusual sites of
VTE, such as cerebrovascular, portal, mesenteric and retinal
veins have also been described. The reason for the increased
risk is not completely understood. Acquired risk factors appear
to be most relevant and many of the haemostatic alterations
parallel inflammatory activity.301 Thus, the majority of VTE
occurs during the active phase of IBD.299
The diagnosis of VTE is not considered in further detail and
should follow international guidelines305,306 based on appro-
priate imaging techniques. The most widely used procedures
are ultrasound and venography for diagnosis of DVT and
ventilation-perfusion scan andmultidetector helical computer
axial tomography for diagnosis of PE.
The mainstay of therapy of acute DVT and PE is
anticoagulation and should follow international guide-
lines.307,308 The benefit of anticoagulant treatment is
independent of the diagnosis of UC. In patients with acute
DVT and/or PE anticoagulant therapy should be continued, if
possible, for at least 3 months using low-molecular-weight
heparin, unfractioned heparin or fondaparinux for initial
treatment followed by vitamin K antagonists. Long-term
treatment should be considered for patients with a second
episode of unprovoked venous thromboembolism.
The risk of bleeding complications of IBD patients under
anticoagulant therapy compared to non-IBD patients is not
known. Major gastrointestinal bleeding may occur, but is rare.
A meta-analysis which evaluated the use of heparin for the
treatment of UC included 8 randomised-controlled trials309 In
6 of 268 patients in the heparin groups an increase in rectal
bleeding was reported: only 3 of them had to be withdrawn
from the study, including one patient who required urgent
surgery. Hospitalisation for an acute medical illness is
independently associated with an 8 fold-increased risk for
VTE.310 This risk can be reduced by anticoagulant prophylaxis
with low-molecular-weight heparin, unfractioned heparin, or
fondaparinux.310,311 The number of IBD patients included in
the studies was too small to draw any sufficient conclusions
about the efficacy of anticoagulant prophylaxis specifically in
IBD.312,313 However, hospitalised IBD patients have a higher
rate of VTE than non-IBD hospitalised patients, with an
associated increased age- and comorbidity-related excess
mortality from VTE298,300 Hospitalised patients with acute
severe or fulminant disease are most appropriately treated
with anticoagulant prophylaxis with low-molecular-weight
heparin, unfractioned heparin, or fondaparinux, especially in
the event of prolonged immobilisation.299,300,311–313 Antico-
agulant prophylaxis after abdominal surgery should follow
established guidelines.310 Non-IBD specific risk factors for VTE
might further increase the risk. Thus, UC patients should be
informed about risk factors for VTE such as oral contraceptive
use and long-distance travel.11.8. Cardiopulmonary disease
Cardiac involvement should be considered not only rare, but
is usually subclinical. The treatment of IBD-related cardiac
21Second European evidence-based consensus on ulcerative colitis' diagnosis and managementinvolvement depends on the specific pattern of involvement
and patients should be seen by a cardiologist. Pulmonary
disease represents the least frequent extraintestinal manifes-
tation of IBD, but it is likely that its true prevalence is
unknown. Respiratory symptoms may be present in N50% of
IBD patients, but these are often mild, attributed to smoking,
or ignored. Drugs, including sulfasalazine, mesalazine and
methotrexate may cause a pneumonitis. Respiratory symp-
toms in patients on anti-TNF therapy should never be ignored,
because it may indicate the onset of serious opportunistic
infection. The treatment of IBD-related respiratory disease
depends on the specific pattern of involvement. Colonic
surgery may aggravate prior airway disease.
11.9. Anaemia
11.9.1. Introduction
The subject of anaemia has previously received little
attention,314 and was not covered as a separate issue in the
first edition of these guidelines. However, anaemia is themost
common extraintestinal manifestation of IBD. It is not always
easy to obtain specific data on UC, but recent epidemiological
data confirm that anaemia occurs frequently in both CD and
UC.315 Anaemia is particularly common in severe disease,
affecting 66% of all inpatients316 and 40% of patients in
referral centres.315 Iron deficiency is more prevalent than
anaemia, being present in up to 45% of IBD patients.316,317
Anaemia is a very relevant clinical condition that may affect
quality of life or the ability to work.318 Furthermore, it can be
associated with severe co-morbidities such as transfusion-
associated hepatitis C, postsurgical complications319 or even
risk of death.320 Most of these facts have been fully recognised
only in recent years,316 and an international group of experts
has developed guidelines.321 And there are other reviews for
the reader looking for more detail.322,323
In UC, the two most important factors are iron deficiency
and active inflammation, while haemolytic anaemia and
drug-induced anaemia are more uncommon.322 Iron defi-
ciency anaemia (IDA) may result from chronic blood loss,
reduced iron intake or absorption, the anaemia of chronic
disease (ACD, also known as anaemia of inflammation) and
anaemia of mixed origin (AMO). Although uncommon,
vitamin B12 or folate deficiency and drug-induced anaemia
(sulfasalazine, thiopurines, methotrexate, calcineurin in-
hibitors) should also be born in mind. Determination of the
causal factors is not only of academic interest: effective
treatment is possible only if the contributing factors in a
particular patient are clearly defined.316
Statement 11M
Anaemia is defined according to the WHO criteria
[EL5, RGD]. The major forms of anaemia in
ulcerative colitis are iron-deficient anaemia,
anaemia of chronic disease and anaemia of mixed
origin [EL5, RG D]
Anaemia is defined by the WHO as a decline in blood
haemoglobin to a concentration of b12 g/dL (120 g/L) inwomen and b13 g/dL (130 g/L) in men. These parameters can
equally be applied to patients with ulcerative colitis. However,
when determining anaemia purely on the basis of haemoglobin
levels, it is important to take account of pregnancy, altitude,
cigarette smoking, and possibly ethnicity.324 Therefore, the
WHO has defined differentiated international cutoff values of
haemoglobin and haematocrit.321
Full evaluation of a patient should include not only
haemoglobin, but also haematological values, iron status,
vitamin B12 and folic acid levels, and inflammation
markers.321
11.9.2. Diagnosis of iron deficiency
Statement 11N
Diagnostic criteria for iron deficiency depend on
the level of colonic inflammation. In patients
without any evidence of inflammation a serum
ferritin level b30 mcg/L or transferrin saturation
b16% define iron deficiency. In the presence of
inflammation, the lower limit of serum ferritin
consistent with normal iron stores is 100 mcg/L
[EL2, RG B]. In the presence of biochemical or
clinical evidence of inflammation, the diagnostic
criteria for anaemia of chronic disease (ACD) are a
serum ferritin N100 mcg/L and transferrin satu-
ration b16%. If the serum ferritin level is between
30 mcg/L and b100 mcg/L a combination of true
iron deficiency and ACD is likely [EL 2, RG B]
Normally, low mean cell volume (MCV) and low mean
corpuscular haemoglobin (MCH) are reliable parameters of
iron deficiency. However, in UC a normal MCV does not exclude
iron deficiency as the cause of anaemia, as patients treated
with azathioprine or 6-mercaptopurine may have normal or
even elevated MCV. Conversely, low MCV does not necessarily
imply iron deficiency, because in the presence of ACD it can
be normal or low.317,325 The accuracy of diagnosis for IDA
can be improved substantially by including iron metabolism
parameters.317,326
Isolated iron deficiency, in the absence of inflammation, is
usually indicated by the combination of low iron, low ferritin
and low transferrin saturation (TfS) with increased transferrin
receptor concentrations (sTfR). However, the diagnosis of iron
deficiency may also be complicated in UC by the fact that, in
this context, iron deficiency and the anaemia of chronic
disease frequently coexist and interact in a complex man-
ner,326 so that a reliable differentiation using these laboratory
methods may be impossible.323 In order to determine the
exact type of anaemia in any specific clinical scenario, a
combination of parameters should be assessed.323
In the absence of biochemical (elevated CRP, leukocyto-
sis) or clinical inflammation, ferritin is a reliable indicator of
iron storage levels. A serum ferritin level b15 μg/L indicates
absolute iron deficiency.321 A TfS level below 16% is also a
sensitive marker of iron deficiency, though it has a low
specificity of only 40–50%.327
considered when there is iron deficiency without
anaemia [EL4, RG D]. Intravenous iron is more
effective and better tolerated than oral iron
supplements [EL1, RG A]. Absolute indications
for intravenous iron include severe anaemia
(haemoglobin b10.0 g/dL), and intolerance or
inadequate response to oral iron [EL1a, RG A].
Intravenous iron should be considered in combina-
tion with an erythropoietic agent in selected cases
where a rapid response is required [EL5, RG D]
22 G. Van Assche et al.However, as ferritin, like transferrin, is affected by
the acute-phase reaction, an increase in serum ferritin
levels can occur in the course of inflammatory processes,
suggesting normal iron status in patients who actually have
iron deficiency. Therefore, measurements of inflammatory
parameters that are independent of iron metabolism (ESR,
CRP) should be carried out to aid diagnosis.321,323
In the presence of biochemical evidence of inflammation,
the lower limit of ferritin consistent with normal iron stores
should therefore be increased to 100 μg/L, and hypoferraemia
should be considered likely if TfS is b16% and serum ferritin is
between 30 and 100 g/L. ACD is likely if serum ferritin is
N100 μ/L and TfS is b16%.321,323,328
If available, the determination of sTfR (high in iron
deficiency, normal or low in ACD) can help to make a correct
diagnosis.328 The haemoglobin concentration in reticulocytes
has been suggested as a more exact indicator of iron stores in
the context of inflammation, and could also be useful in
monitoring response to therapy, although direct experience in
IBD is limited.323,329 The main message for the clinician is that
the evaluation of anaemia in any given patient is always
incomplete if the inflammatory status is not clearly defined.11.9.3. Treatment of anaemia and iron deficiency
Statement 11O
Treatment should be considered for all patients with
a haemoglobin level below normal. The approach to
treatment depends mainly on symptoms, the sever-
ity of anaemia and aetiology [EL4, RG D]
Chronic inflammation is frequently a key issue leading to
the development of anaemia in patients with UC, and the
likelihood of anaemia increases with the severity of the
colitis.316 Treating the underlying UC is therefore the first
step in the treatment of anaemia. However, this alone is
rarely sufficient to normalise haemoglobin levels and in real
clinical practice there is clear evidence that anaemia is
often undertreated.315,321
As previously stated, anaemia has a profound effect on the
quality of life. Normalisation of the haemoglobin level is
therefore an objective and auditable goal of the treatment of
UC.316,321 In clinical practice, recurrence of anaemia is common
(N50% after 1 year), and is often indicative of ongoing intestinal
inflammation.330 Long-termmonitoring of patients successfully
treated for anaemia appears warranted in order to detect and
treat those with recurrent anaemia. Therefore UC patients in
remission, and those with mild disease, should be monitored
every 12 and 6 months respectively.321 Vitamin B12 and folate
levels should be checked at least annually, or if macrocytosis is
present.321Statement 11P
Iron supplementation should be initiatedwhen iron
deficiency anaemia is present [EL1, RG A] andIf anaemia is present and iron deficiency is proven, iron
supplementation should be commenced.331 In cases of iron
deficiency without anaemia, an individualised approach is
required. The main goal of therapy for IDA is to supply
sufficient iron to increase haemoglobin levels by N2 g/dL
or increase them to normal values within 4 weeks, to
replenish iron stores (transferrin saturation N30%), to relieve
anaemia-related symptoms, and to improve quality of life.
Transferrin saturation levels N50% and ferritin levels
N800 g/L are considered toxic and should be avoided.321
In current practice, the Ganzoni Formula (iron deficit
[mg]=body weight [kg]×(target Hb−actual Hb [g/dL]×
2.4)+stored iron (500 mg)) is used to calculate individual
iron requirement.332 However, this formula is inconvenient,
error-prone, inconsistently used in clinical practice, and
almost certainly underestimates iron requirements in
IBD.333
Iron supplementation can be administered orally, intra-
muscularly or intravenously. The choice of supplementation
method is determined by the symptoms, aetiology and
severity of the condition, the dynamics of the haemoglobin
decrease, co-morbidities and risks of therapy.321,323 For many
years, oral iron supplementation has been the preferred
therapy. The use of intravenous iron preparations has been
considered a last resort due to safety concerns.334 Some
patients may respond to oral iron. A very detailed observa-
tional study has demonstrated that patients with mild
anaemia (Hb N10 g/dL) can be adequately treated according
to current guidelines321 with 100 mg/day iron sulphate.335
However, as more than 90% of ingested iron remains
unabsorbed, oral iron preparations frequently lead to the
occurrence of gastrointestinal adverse effects, including
nausea, flatulence, diarrhoea and gastric erosion. Moreover,
animal and human studies indicate that the generation of
reactive oxygen species (Fenton reaction) by non-absorbed
iron can potentially lead to the exacerbation of IBD.335–339 On
the other hand, intramuscular iron supplementation should be
avoided,323 since there is no clear clinical evidence demon-
strating it to be less toxic or more effective than oral or
intravenous iron.
In recent years, several safe IV iron preparations have
become available and have become the standard of care for
iron replacement in some circumstances in the fields of
nephrology and oncology.334,340,341
Despite a number of observational and controlled studies in
UC and CD demonstrating that IV iron is not only clinically
effective but also safe, gastroenterologists still seem hesitant
to administer iron intravenously.328 Several non-randomised321
and randomised studies342–344 have shown that IV iron is at least
23Second European evidence-based consensus on ulcerative colitis' diagnosis and managementas effective as oral iron, delivers faster response rates, and is
safer in all but a very few patients who may experience
side-effects. Intravenous iron therapy is advisable in the
following cases: for iron-deficient patients who are intolerant
or unresponsive to oral iron supplementation (i.e., those
demonstrating an insufficient increase in serum iron parame-
ters within the first 2 weeks of treatment); for patients with
severe anaemia (haemoglobin level b10 g/dL (100 g/L)); for
patients with pronounced disease activity; and for patients who
are being treated with erythropoiesis-stimulating agents.323
Statement 11Q
Erythropoietic therapy should be considered, when
anaemia does not improve in spite of intravenous
iron therapy and control of inflammation [EL 2, RG
B]. To optimise the effect of erythropoietic agents
treatment should be combined with intravenous
iron supplementation [EL 2, RGB]
In some patients, treatment of the underlying IBD in
conjunction with iron, folic acid and vitamin B12 supplemen-
tation is insufficient to correct anaemia. In such cases,
treatment with erythropoiesis-stimulating agents (ESA) is a
valid option.345 A randomised clinical trial demonstrated
that erythropoietin combined with IV iron was effective in
correcting anaemia in most patients with IBD, which has
been confirmed in other studies.314,345,346 There are limited
data on the exact dose and drug to be used, and in this
rapidly changing field, local expertise from haematologists
or nephrologists can be helpful.345 However, individual
dosage and therapeutic success are critically dependent
not only on the availability of sufficient iron, but also on the
level of inflammation activity. Increased erythropoiesis
requires additional iron for the production of haem; iron
supply is regarded as optimal when the transferrin saturation
is calculated to be 30–40% and the serum ferritin concentra-
tion amounts to 200–500 mcg/L.321,323 Therapy with
erythropoiesis-stimulating agents should therefore always be
combined with intravenous iron administration, as functional
iron deficiency can essentially always be expected.321,323 It
should be kept in mind that the use of ESA is a risk factor for
thrombosis, an otherwise common complication in IBD and
particularly in UC. Extensive experience in oncology and
nephrology347,348 suggests that the therapeutic goal with ESA
should therefore be a haemoglobin of 11–13 g/dL. It is not
clear whether the same goal can be applied to treatment of
anaemia in patients with IBD.
Statement 11R
Blood transfusion should be restricted to very
special clinical situations, such as acute severe
anaemia with hemodynamic instability, severe
anaemia-related weakness and fatigue and/or
failure of all other treatments [EL 5 RG D]Red blood cell (RBC) transfusion was rather frequently
used in the past. However, even though infectious risks have
been greatly reduced,349 RBC transfusions are still associat-
ed with increased risks of venous and arterial thrombotic
events,350 acute and delayed transfusion reactions, and
transfusion-induced immunomodulation.317,349,351 Further-
more, red blood cells are an expensive and scarce resource.352
Therefore, the use of RBC transfusion should be limited only to
certain specific situations: acute anaemiawith haemodynamic
instability, severe anaemia-related fatigue, and/or failure of
other treatments.Acknowledgements
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